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1. Introduction 
Metal compounds in medicine: a short overview  
Since the antiquity transition metals have been used as therapeutic agents on a simple 
empirical basis, in some cases with appreciable results. Among these, silver, gold and 
mercury salts have been extensively employed to treat various bacterial diseases such 
Tuberculosis, Syphilis and Gonorrhea [1-3]. Anyway, more recently, due to the 
discovery of Penicillin G (Fig.1) [4] and to grounded concerns on their conspicuous 
systemic toxicity, metal-based agents were gradually abandoned.  
 
Fig.1: The molecular structure of Penicillin G. 
Nowadays only a few metal-based compounds resist in clinical use, but, despite their 
low appeal in current research, transition metals are still of great importance in 
Medicinal Chemistry. Indeed, since the serendipitous discovery of the anticancer 
properties of Cisplatin in the late 1960s [5] (a simple Platinum(II) compound 
synthesized for the first time by Peyrone in 1844 [6]) and its approval in 1978 by the 
FDA for the treatment of testicular and ovarian cancer [7-9], metal-based drugs have 
gained a great interest in academic research. This unexpected discovery encouraged 
scientific community to investigate the properties of other Platinum related 
compounds and in a few decades other two diamminoplatinum-based molecules, i.e. 
Carboplatin and Oxaliplatin, were approved worldwide for the treatment of neoplastic 
diseases (Fig.2) [10, 11]. 
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Fig.2: The three platinum related compounds approved worldwide for the treatment 
of cancer. 
The introduction in clinical use of Platinum compounds has represented a revolution in 
the field of oncology and medicinal chemistry: as showed in Fig.3 [12], since the 
approval of clinical protocols based on Cisplatin, the death rate in the USA due to lung 
cancer stops for the first time his growth.  
 
Fig.3: Lung cancer death rates per 100000 peoples (males) in the United States since 
1950 to 2002 [12]. 
 6 
 
At present days Cisplatin, Carboplatin and Oxaliplatin still represent the most important 
established molecules for the treatment of malignances. Anyway, despite these 
impressive results obtained in the cure rate of oncologic patients, chemists are still 
looking for other valuable structures. This intense research is fully justified by the 
relevant flaws showed from the Cisplatin related compounds. Indeed, despite their high 
activity against tumoral cells, these molecules usually show invalidating side effects on 
treating patients (nephrotoxicity, ototoxicity, neurotoxicity, severe nausea and 
vomiting, hemolitic anemia and electrolytic disturbance) [13]. Another central topic 
concerning the administration of established Platinum compounds, is the development 
of drug resistance by cancer cells due to a low drug uptake [14]. The efforts of scientists 
for solving these problems have conducted to the development of new structures 
(some of them, such as Nedaplatin, Heptaplatin, Lobaplatin approved in specific areas 
[15-17]), but none of the new Platinum(II) compounds has reached the goal of solving 
the above mentioned problems. Ironically, after four decades since his approval, 
Cisplatin in still the most important anticancer agent.  
Due to these considerations, the scientists have moved their attention on octahedral 
Platinum(IV) compounds. Indeed, due their high kinetic inertia, Platinum(IV) complexes 
are usually less reactive towards non wanted targets such serum proteins due to a 
higher stability. This property should contribute, at least in principle, to reduce the 
severe side effects associated to Platinum(II) compounds. More precisely, Platinum(IV) 
compounds act as prodrugs. Indeed, they are usually inert until their activation, that 
usually occurs through a redox process possible only in the reducing environment of 
cellular cytosol, followed from the release of two axial ligands (Fig.4) [18]. 
 
Fig:4: Reduction mechanism of Platinum(IV) prodrugs. 
For expanding the possibilities of discovering new valuable structures, the interest of 
chemists had moved from Platinum to other transition metals. Indeed, in four decades 
of research concerning d block, many examples of complexes with interesting 
anticancer and antimicrobial activity have been reported in literature (based, for 
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example, on Iron, Copper, Silver, Iridium, Rhodium, Palladium and more others) [19-
22]. In Fig.5 are reported some examples of Silver N-heterocyclic carbenes showing 
interesting anticancer properties: the activity of these compounds turned out to be in 
the nanomolar range (30-75 nM) against HCT116, MCF-7 and HL-60 cell lines [23]. 
 
Fig.5: Examples of Silver N heterocyclic carbenes active in the nanomolar range against 
different cancer models (HCT116, MCF-7 and HL-60) [23]. 
Anyway, the most promising alternatives are actually limited to a few other transition 
elements such Ruthenium and Gold. More precisely, many Ruthenium derivatives have 
demonstrated interesting anticancer properties [24]. In particular, some imidazole and 
indazole derivatives such NAMI-A and KP1019 (Fig.6) reached the clinical trials and 
showed the capability of inhibiting the cellular growth associated with a lower 
cytotoxicity and lower side effects in comparison with Cisplatin and its derivatives [25]. 
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Fig.6: NAMI-A and KP1019 structures. 
Other compounds of interest are, undoubtedly, the molecules bearing a Gold(III) 
center. As in the case of Platinum(II) complexes, Gold(III) molecules show square-planar 
coordination geometry.  For this reason, based on their structural and electronic affinity 
to Cisplatin and cisplatin-related antitumor drugs, Gold(III) species represent a 
promising class of potential anticancer agents. However, the development of Gold(III) 
complexes as therapeutic drugs has been hampered by their low stability under 
physiological conditions and remains a critical parameter in the drug development of 
these species. More precisely, in comparison with Platinum(II) compounds, Gold(III) 
analogues turned out to be light sensitive and to undergo easy reduction to metallic 
gold under physiological conditions [26]. Anyway, kinetically stable Gold(III) complexes 
with various ligands have been prepared and biologically investigated. Most of them 
are complexes with Au–N bonds (eventually containing additional Au–O and Au–Cl 
bonds) but also some species with Au–S or Au–C bonds and their bioactivities have 
been described (Fig.7) [27]. 
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Fig.7: Examples of Gold(III) complexes [27]. 
On the other hand, the linear Gold(I) complexes show a greater stability associated with 
many interesting pharmacological properties: many of them act as 
immunosuppressive, anti-inflammatory, antiretroviral and anticancer compounds. At 
present days Sodium Aurothiomalate and Auranofin (Fig.8), two examples of this class 
of molecules, are established drugs in clinical use for the treatment of severe forms of 
autoimmune rheumatoid arthritis [28]. 
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Fig.8: Structures of Sodium Aurothiomalate and Auranofin, respectively. 
Moreover, in the frame of a repurposing approach of already established drugs, the 
latter of these two compounds has recently gained a growing attention of bioinorganic 
community due to its antibacterial, antiparastitic and anticancer activity [29].  
The purpose of the thesis 
For all these reasons, the research concerning metal-based compounds as possible 
antimicrobial or anticancer candidates, is a field of interest still keeping valuable 
alternatives to organic chemistry. The aim of this work is to present the most relevant 
results obtained in the years of my PhD, more precisely, all the data presented in this 
thesis are extracted from the following papers (from chapter 2 to chapter 7, 
respectively): 
• D. Cirri, S. Pillozzi, C. Gabbiani, J. Tricomi, G. Bartoli, M. Stefanini, E. Michelucci, 
A. Arcangeli, L. Messori, T. Marzo, Dalton Trans., 2017, 46, 3311–3317. 
• T. Marzo, A. Pratesi, D. Cirri, S. Pillozzi, G. Petroni, A. Guerri, A. Arcangeli, L. 
Messori, C. Gabbiani, Inorganica Chimica Acta, 2018, 470, 318–324. 
• T. Marzo, D. Cirri, S. Pollini, M. Prato, S. Fallani, M. I. Cassetta, A. Novelli, G. M. 
Rossolini, L. Messori, ChemMedChem, 2018, 13, 2448–2454. 
• T. Marzo, D. Cirri, C. Gabbiani, T. Gamberi, F. Magherini, A. Pratesi, A. Guerri, 
T. Biver, F. Binacchi, M. Stefanini, A. Arcangeli, L. Messori, ACS Med. Chem. 
Lett., 2017, 8, 997−1001. 
• T. Marzo, L. Massai, A. Pratesi, M. Stefanini, D. Cirri, F. Magherini, M. Becatti, I. 
Landini, S. Nobili, E. Mini, O. Crociani, A. Arcangeli, S. Pillozzi, T. Gamberi, L. 
Messori, ACS Med. Chem. Lett., 2019, 10, 656−660. 
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• M. G. Fabbrini, D. Cirri, A. Pratesi, L. Ciofi, T. Marzo, A. Guerri, S. Nistri, A. 
Dell’Accio, T. Gamberi, M. Severi, A. Bencini, L. Messori, ChemMedChem, 2019, 
14, 182–188. 
The above mentioned chapters were written as an independent sections, containing 
each of them its own introduction to the specific problem and its conclusions. Anyway, 
all the chapters of the document are linked from drug discovery as a common thread. 
More precisely, chapters from 2 to 6 are dedicated to a “small modification approach” 
merged with repurposing strategies. Indeed, all the presented molecules were 
obtained from minor modifications of two parent compounds, i.e Oxaliplatin (Fig.2) and 
Auranofin (Fig.8). The choice of modifying two clinically established compounds comes 
from the advantages of dealing with molecules owning an already know 
pharmacological profile, and from the possibility of elucidating some structure-activity 
relationships. On the other hand, chapter 7 is dedicated to the study of a fluorescent 
complex belonging to the class of Silver N-heterocyclic carbenes, being these 
compounds very interesting due their high activity against many tumoral cell lines. 
Moreover, the presence of a fluorescent probe bounded on the structure, allowed to 
perform some confocal studies for determining the biodistribution of the complex 
inside the cells.   
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2. Platinum(II) compounds as promising 
chemotherapeutic agents: the case of PtI2(DACH) 
Introduction 
Today, colorectal cancer (CRC) is the fourth most common cause of death due to cancer 
worldwide. Prognosis is highly correlated with TNM staging (widely used cancer staging 
system. T refers to the size and extent of the primary tumor; N refers to the number of 
nearby lymph nodes that have cancer; M refers to whether the cancer has 
metastasized. Numbers after each letter are used to give more details on the stage of 
a tumor), with a 5-year survival of 90% for patients in earlier stages but less than 25% 
for those with metastatic disease [1]. The cornerstone of therapy is represented by “en 
bloc” surgical resection of tumour and regional nodes, although perioperative 
chemotherapy may provide important advantages in subjects with advanced disease 
and metastases [2]. Adjuvant chemotherapy for CRC mainly relies on fluoropyrimidine 
compounds combined with platinum-based drugs, mainly cisplatin and its analogue 
oxaliplatin. Oxaliplatin (Eloxatin™) is a third-generation platinum compound approved 
by United States Food and Drug Administration (FDA) in 2002 for the treatment of 
advanced colorectal cancer. To date thousands of patients worldwide have been 
treated with oxaliplatin, especially in combination with other drugs [3]. Indeed, either 
the FOLFOX (5-FU, leucovorin, and oxaliplatin) or CapeOx (capecitabine and oxaliplatin) 
regimens are used most often [4, 5]. Despite its success, important side effects such as 
acute and chronic neurotoxicity are, still today, limiting factors to its clinical use [6]. 
With the aim to overcome the main drawbacks of oxaliplatin treatment i.e. side effects 
as well as frequent intrinsic or acquired pharmacological resistance, in the last few 
decades, many analogues of this clinically established drug have been synthesised and 
tested [7–11]. In this framework, we have prepared the oxaliplatin analogue {(1R,2R)-
cyclohexane-1,2-diamine}diiodidoplatinum(II), (PtI2(DACH) hereafter) (Fig.1) where the 
bidentate oxalate ligand of oxaliplatin is replaced by two iodide ligands.  
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Fig. 1: Schematic drawing of oxaliplatin and its iodide analogue. 
Notably, this oxaliplatin derivative was reported and structurally characterised in 2011 
by R. Pažout and coworkers [12], but no biological studies were then attempted. 
Reasons that make PtI2(DACH) of particular interest for inorganic medicinal chemists 
are essentially twofold. 
(i) We believe that the replacement of the bidentate oxalate ligand with two iodides 
may affect mainly the activation process of the Pt centre, both kinetically and 
thermodynamically, influencing accordingly its overall biological profile. 
(ii) In addition, insertion of two iodide ligands in the place of oxalate is expected to 
increase considerably the lipophilic character of the resulting drug hopefully enhancing 
cellular uptake and bioavailability. 
It is worth reminding that this kind of strategy was recently exploited, in our research 
group, and applied to cisplatin. Indeed, the iodide analogue of cisplatin was prepared, 
characterised and shown to possess interesting chemical and biological properties that 
are definitely distinct from those of cisplatin [13]. The obtainment of the desired Pt 
compound, i.e. PtI2(DACH), was confirmed and supported by NMR and CHN analysis. 
Afterward, the complex was studied in depth in terms of its solution behaviour and its 
interactions with model proteins (i.e. lysozyme, RNase) and with a short single strand 
oligonucleotide bearing the GG motif. Also, cytotoxic and proapoptotic effects were 
investigated in a few representative CRC cell lines and mechanistic hypotheses for the 
different pharmacological effects were proposed. Finally, uptake experiments were 
carried out to assess whether the replacement of the oxalate ligand with two iodide 
ligands affords indeed an enhanced uptake hopefully improving the drug’s 
bioavailability. 
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Experimental 
Chemicals and reagents 
Chemicals were purchased from Sigma-Aldrich and used without further purification. 
Dodecameric oligonucleotide ODN2, with sequence CTACGGTTTCAC and proteins were 
also purchased from Sigma-Aldrich. 
Chemistry 
Synthesis and characterisation of PtI2(DACH): For the synthesis of PtI2(DACH), 99.3 mg 
of K2PtCl4 (2.4 × 10−4 mol), have been solubilised in 1.5 mL of MilliQ water. A water 
solution (2 mL) of KI (158.7 mg, 9.6 × 10−4 mol) was added to K2PtCl4 and stirred (50 °C) 
in the dark for five minutes until quantitative conversion of K2PtCl4 to K2PtI4 was 
obtained. 1,2-Diaminocyclohexane (1R,2R)-(−): DACH (27.3 mg, 2.4 × 10−4 mol) was 
then solubilised in 2 mL of MilliQ water and the obtained solution was slowly added to 
the K2PtI4 water solution. After a further four hours of stirring, a precipitate appeared, 
and complete precipitation of yellow crystals of PtI2(DACH) occurred overnight at room 
temperature. The solid was then collected through vacuum filtration and washed with 
hot water, ice-cooled ethanol and ether. 135.5 mg of PtI2(DACH) were obtained (yield 
81%). The complex was characterised by NMR and elemental analysis.  
1HNMR (DMFd7, 400.13 MHz, 298 K): 5.56 (b, 1H); 4.96 (b, 1H); 2.50 (t, J = 8 Hz, 2H); 
2.23 (d, J = 12 Hz, 2H); 1.56 (m, 4H); 1.15 (m, 2H). 
Elemental analysis of C, N and H [calculated C: 12.8%, H: 2.32%, N: 4.98%, experimental: 
C: 12.5%, H: 2.32%, N: 4.86%];  
Log P value determination 
The octanol–water partition coefficient for PtI2(DACH) was determined by modification 
of the reported shake-flask method. Water (50 mL, distilled after MilliQ purification) 
and n-octanol (50 mL) were shaken together for 72 h to allow saturation of both phases. 
A solution of the complex was prepared in the water phase (3 × 10−3 M) and an equal 
volume of octanol was added. Biphasic solutions were mixed for ten minutes and then 
centrifuged for five minutes at 6000 rpm to allow separation. Concentration in both 
phases was determined by UV-Vis. Reported log P is defined as 
log[complex]oct/[complex]wat. Final values were reported as mean of three 
determinations. 
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UV-Vis experiments 
Solution behaviour of PtI2(DACH) was assessed through spectrophotometric 
experiments performed with a Varian Cary 50 Bio UV-Vis spectrophotometer (1 cm 
pathlength quartz cell) in buffered solutions without the use of DMSO and NaCl. A 
solution of the complex (10−4 M) was prepared in 50 mM phosphate buffer at pH = 7.4. 
The absorbance was monitored in the wavelength range between 200 and 800 nm for 
72 h at 25 °C. 
ESI-MS experiments 
The ESI-MS spectrum of the ODN2–PtI2(DACH) mixture was recorded by direct injection 
at 5 μl/min flow rate in an Orbitrap high-resolution mass spectrometer (Thermo, San 
Jose, CA, USA), equipped with a conventional ESI source. The working conditions were 
as follows: negative polarity, spray voltage −2.7 kV, capillary voltage −20 V, capillary 
temperature 280 °C, tube lens voltage −113 V. The sheath and the auxiliary gases were 
set at 23 and 4 (arbitrary units), respectively. For acquisition, Xcalibur 2.0 software 
(Thermo) was used and deconvoluted masses were obtained by using the ProMass 2.8 
rev. 2 tool for Xcalibur (Novatia). 
ESI-MS spectra of the PtI2(DACH)–protein mixtures were recorded by direct injection at 
3 μL/min flow rate in the same instrument. The working conditions were as follows: 
positive polarity, spray voltage 3.1 kV, capillary voltage 45 V, capillary temperature 220 
°C, tube lens voltage 230 V. The sheath and the auxiliary gases were set at 17 and 1 
(arbitrary units), respectively. For acquisition, Xcalibur 2.0 software (Thermo) was used 
and deconvoluted masses were obtained by using the integrated Xtract tool. For 
spectra acquisition a nominal resolution (at m/z 400) of 100 000 was used. 
Chemicals and drugs 
For cellular experiments, cisplatin, cis-PtI2(NH3)2, oxaliplatin and PtI2(DACH) were 
dissolved in MilliQ water at the concentration of 8.3, 1, 5 and 1 mM, respectively. All 
stock solutions were stored at −20 °C. 
Cell culture 
Human colorectal cancer cell lines (HCT-116, HCT-8 and HT29) and mouse fibroblast 
cell line L929 were cultured in RPMI-1640 medium (Euroclone; Milan, Italy), 
supplemented with 2% L-Glut, 10% fetal bovine serum (FBS) and 1% 
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penicillin/streptomycin (complete medium). HT29 cells were kindly provided by Dr R. 
Falcioni (Regina Elena Cancer Institute, Rome). 
Cell viability assay 
To evaluate the IC50 of each compound, cell viability was assessed through the Trypan 
Blue exclusion test (Sigma-Aldrich). Cells were seeded at 1x104 per well in 96-well plates 
(Costar Corning) in complete medium and incubated for 24 h before the compound was 
added. Following the addition, cells were further incubated for 24 hours. Cells were 
then harvested and counted by the Trypan Blue exclusion test using a hemocytometer. 
All experiments were performed in triplicate. The IC50 values were calculated for each 
cell line and data fitted using a Hill1-type equation by using Origin Software (Microcal 
Origin 8.0 software; OriginLab Corporation, Northampton, MA). 
Proliferation experiments 
HCT116 cells were seeded at 1x104 per well in 96-well plates (Costar Corning) in 
complete medium and incubated for 24 h before the compound was added. After 24, 
48 and 72 h of incubation viable cells (determined by the Trypan Blue exclusion test) 
were counted in triplicate using a haemocytometer. Each experimental point 
represents the mean ± sem of three separate experiments. 
Cell cycle analysis 
Cell cycle distribution was assessed by flow cytometry after staining the cells with 
propidium iodide (PI). Cells were seeded and treated generally with different 
compounds at their IC50 (unless otherwise noted in the figure legend) for 24 h. At the 
end of incubation, cells were harvested, washed with PBS and resuspended in 300 μl 
propidium iodide staining solution and incubated in the dark for 20 minutes at room 
temperature. The DNA content of the cells was measured by using a BD FACSCanto 
(Becton Dickinson, Franklin Lakes, NJ, USA) and the percentage of cells in each cell cycle 
phase was determined using ModFit LT 3.0 analysis software (Verity Software House, 
Topsham, ME, USA). 
Annexin/PI assay 
Apoptosis was determined through the Annexin V/propidium iodide test (Annexin-
VFLUOS staining kit; Roche Diagnostics, Mannheim, Germany). Cells, treated as above, 
were harvested after 24 h of treatment with different compounds (at their IC50 value, 
unless otherwise noted in the figure legend), washed with PBS, re-suspended in 100 μL 
of buffer and incubated with FITC-conjugated Annexin V and propidium iodide for 15 
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min. Flow cytometry was performed using the BD FACSCanto (Becton Dickinson, 
Franklin Lakes, NJ, USA). Data were analysed through the BD FACSDiva Software 6.1.3. 
Statistical analysis 
Data are generally given as mean values ± standard error of the mean (sem), unless 
otherwise specified in the figure legend. The normality of data distribution was checked 
with the Kolmogorov–Smirnov test. For multiple comparisons, we used one-way 
ANOVA, with the post-hoc Bonferroni test to derive P values. 
Uptake measurement 
The determination of platinum concentration in the cellular pellets was performed by 
using a Varian 720-ES Inductively Coupled Plasma Atomic Emission Spectrometer (ICP-
AES) equipped with a CETAC U5000 AT+ ultrasonic nebulizer, in order to increase the 
method sensitivity as fully described in [13]. 
Results and discussion 
Synthesis and characterization of PtI2(DACH) 
The synthesis of PtI2(DACH) was performed as described in the Experimental section, 
with a good yield. Synthesis started from K2PtCl4 that was quantitatively converted into 
K2PtI4. In contrast to previously reported synthetic routes [12], 1,2-
diaminocyclohexane(1R,2R)-(−) was used in the place of DACH tartrate and slowly 
added to K2PtI4, at room temperature. The purity of the resulting product was checked 
by 1HNMR and elemental analysis and found to be >95%. A detailed description of all 
the procedures and of the chemical characterization is given in the experimental 
section. Remarkably, in the 1HNMR spectrum, the two signals at 4.96 and 5.56 ppm, are 
assignable to the ammine protons. This attribution was validated by a direct 
comparison with the spectrum of PtCl2(DACH) previously synthesized and recorded 
under the same conditions. It is interesting to note that in contrast to PtCl2(DACH) for 
which the two signals attributable to the amine protons can be suppressed by adding 
D2O to the DMF-d7 sample solution, for PtI2(DACH) the exchange of a proton with 
deuterium (and thus amine signals suppression), doesn’t occur even after 24 h after 
the addition of deuterated water, indicating that the replacement of chloride with 
iodide ligands strongly decreases the mobility of amine protons. 
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Log P determination 
The octanol/water partition coefficient is an important parameter in drug design with 
a large impact on the overall ADME profile of the drug itself. Generally speaking, a more 
lipophilic character commonly facilitates cellular drug uptake and bioavailability. 
However, the situation is somewhat more complex when dealing with a prodrug 
requiring chemical activation prior to performing its pharmacological actions as is the 
case for anticancer Pt compounds. A log P value of 0.76 was determined for PtI2(DACH) 
by modification of the classical flask method previously used (see the Experimental 
section for further details) [13, 14]. For comparison purposes log P values for a few 
parent Pt complexes are also reported in Table 1.  
 
Table 1: Log P values for Pt-based drugs Complex Log P value. 
As expected, the bis-iodide analogue i.e. PtI2(DACH), manifests a far larger lipophilic 
character than oxaliplatin, being the most lipophilic compound in the series. 
Solution chemistry 
PtI2(DACH) may be easily solubilised under physiological-like conditions (i.e. in 
phosphate buffer) upon short sonication, thus avoiding the use of DMSO and the 
associated chemical interferences. The solution behaviour of PtI2(DACH) was then 
assessed through UV-Vis analysis. Similarly to cis-PtI2(NH3), PtI2(DACH) shows two main 
absorption bands located at 280 and 350 nm (Fig. 2) [13].  
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Fig. 2: Time course spectra of PtI2(DACH), 10−4 M in 50 mM phosphate buffer recorded 
over 72 h, RT. 
With time, the intensity of both bands slowly decreases; the residual band intensity 
after 72 hours is only ∼20% of the original intensity according to a roughly 
monoexponential decay. The observed spectral changes are ascribed to the progressive 
release of the two iodido ligands [13, 14] with the hydrolysis of PtI2(DACH) significantly 
slower than cis-PtI2(NH3)2 but faster than oxaliplatin (see Table 2). 
 
Table 2: kobs was calculated fitting the variation of absorbance as function of time with 
a single exponential function (UV-Vis time course spectra of complexes, 10−4 M in 50 
mM phosphate buffer recorded over 72 h, RT). 
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Biomolecular interactions of PtI2(DACH) 
Next, to study its interactions with model biological targets, cis-PtI2(DACH) was 
incubated with two model proteins i.e. hen egg white lysozyme and RNase (see the 
Experimental section for details) and the possible adduct formation was investigated. 
These two proteins were chosen since their structures have been often used to 
characterize the interactions occurring between proteins and metallodrugs; in addition, 
crystal structures of their adducts with both cisplatin and oxaliplatin are available [17–
20]. Notably, these model proteins are well suitable also for ESI-MS studies, offering a 
very important substrate for comparative mechanistic studies of metal-based drugs. In 
both cases no metallodrug–protein adduct was detected, indicating that PtI2(DACH), in 
contrast to oxaliplatin, is not able to bind these proteins [18–20]. An explanation for 
this unexpected behaviour is not straightforward. We previously reported that 
coordination of oxaliplatin to lysozyme and RNase implies a multi-step reaction at the 
level of aspartate residues. First, non-covalent coordination of oxaliplatin to the protein 
occurs; then detachment of one oxygen atom of oxalate from Pt coordination (a ring-
opening step leading to monodentate oxalate) is observed with concomitant Pt 
coordination of the carboxylate group from an aspartate residue. Finally the oxalate 
ligand is fully released [19, 20]. We might hypothesize that, this multi-step mechanism 
is inhibited when the oxalate ligand is replaced by two iodides due to the lack of 
“recognition” of intact PtI2(DACH) by these model proteins. Conversely, and in analogy 
with its parent drug oxaliplatin, PtI2(DACH) interacts extensively with a standard 
oligonucleotide bearing the GG motif (ODN2) through a classical reaction pattern 
involving preferential release of iodide ligands (Fig. 3) [21].  
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Fig. 3: Deconvoluted ESI-MS spectrum of PtI2(DACH) 10−4M incubated with ODN2 in LC-
water 72 h, 37 °C, metal to oligonucleotide ratio 1 : 1. 
These results are fully supported by theoretical calculations of ESI-MS peaks (Figure 4). 
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Fig.4: Simulated spectra of 6- charge state of ODN2 + [Pt(DACH)]2+. 
Cellular effects 
We then measured the cytotoxic effects of PtI2(DACH) in a small panel of CRC cell lines 
(HT-29, HCT-116, HCT-8) in comparison with cisplatin, oxaliplatin and cis-PtI2(NH3)2. A 
normal cell line (L929 fibroblast cells) was also included. The cis-PtI2(NH3)2 compound 
was also evaluated since we previously showed that it is fairly active on a cisplatin 
resistant CRC cell line, and can hence be considered a potential drug candidate to 
overcome Pt resistance, at least partially [13]. Cells were exposed to increasing 
concentrations of the drugs, given in the 0–300 μM range, for 24 hours, and the 
respective IC50 concentrations were determined (Table 3). 
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Table 3: IC50 (μM) of cisplatin, cis-PtI2(NH3)2, oxaliplatin and PtI2(DACH) in HT29, 
HCT116 and HCT8 CRC cell lines, as well as in a normal fibroblastic cell line (L929). Cell 
vitality was measured after 24 hours of treatment with the four different compounds, 
by the Trypan Blue exclusion test. IC50 values (means ± sem of four independent 
experiments) were calculated using the Origin Software (Microcal Origin 8.0 software; 
OriginLab Corporation, Northampton, MA) fitting experimental data with Hill1 type 
equation.  
In line with our previous results [13], cis-PtI2(NH3)2 turned out to be more active than 
cisplatin, and even more compared to oxaliplatin, especially in the case of partially 
cisplatin-resistant cell lines HT29 and HCT116. Though less cytotoxic than cisplatin and 
slightly less cytotoxic than oxaliplatin, PtI2(DACH) was more effective than oxaliplatin 
in HCT116 cells that are poorly sensitive to either compounds. These data point out 
that PtI2(DACH) maintains appreciable cytotoxic properties, not different from, and in 
some cases even better than oxaliplatin. This implies that the replacement of oxalate 
with two iodide does not impair the cellular effects of this drug that may be attributed 
mainly to the [Pt(DACH)]2+ chemical moiety. Additionally, when evaluating the effects 
of all compounds on the fibroblast cell line L929, we can state that the cytotoxicity is 
on the whole similar and rather low, with the iodide analogue of oxaliplatin being 
slightly less cytotoxic. Based on these results we studied in detail the effects that Pt 
compounds produce on HCT-116 cells, determining both the distribution of the cells in 
the various phases of the cell cycle and the percentage of cells in the early apoptotic 
phase. These effects were measured in the absence or in the presence of the four 
compounds tested at their respective IC50 values. None of the tested Pt compounds 
caused relevant variation of cell cycle distribution of HCT 116 cells (Table 4 and Fig. 5).  
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Table 4: Cell cycle distribution of HCT 116 cells after 24 hours of treatment with the 
four different compounds at the IC50 values shown in Table 3. Data are means ± sem 
of three independent experiments, and are expressed as percentage of cells in each 
phase of the cell cycle, determined by flow cytometry after staining the cells with 
propidium iodide (PI). 
 
Fig.5: Representative histograms of data reported in Table 4. 
On the contrary, both cisplatin and oxaliplatin increased the percentage of early 
apoptotic cells, as expected (Fig. 6A). Furthermore, the two iodide analogues showed 
an even more evident pro-apoptotic effect, higher than cisplatin and oxaliplatin. 
Interestingly, the analysis of dot plots (Fig. 6B) showed a shifting of the Annexin V/PI 
labelled population to higher fluorescence in HCT116 cells treated with PtI2(DACH) 
compared to oxaliplatin. This suggests that the iodide compound exerts a stronger, 
possibly earlier, pro-apoptotic effect in HCT116 cells, which poorly respond to both 
cisplatin and oxaliplatin. 
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Fig.6: Percentage of early apoptotic HCT 116 cells (determined as Annexin V+/PI-cells) 
after 24 hours treatment with the four different compounds at the respective IC50 
values. Histograms (panel A) are means ± sem of three independent experiments. B: 
Representative dot plots of the Annexin V/PI assay relative to treatments with 
oxaliplatin and PtI2(DACH). 
Pt uptake studies 
Afterward, to confirm whether the enhanced lipophilic character of PtI2(DACH) was 
related to an increase in drug internalisation, comparative uptake experiments were 
carried out on the HCT116 cell line. The results reveal that upon replacement of oxalate 
with iodide, a dramatic enhancement of cellular uptake (∼7 fold increase) takes place 
(Table 5) most likely related to the strong increment in the lipophilic character. 
 
Table 5: Platinum level (per cell) measured after exposure (24 hours) of cell lines to 25 
μM of oxaliplatin and cis-PtI2(DACH). 
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Conclusions 
Despite the success of novel targeted anticancer therapies, cytotoxic platinum drugs 
still remain a cornerstone in the treatment of CRC being largely used in 
chemotherapeutic regimens combined with other cytotoxic molecules. Yet, clinically 
established Pt drugs, e.g. cisplatin and oxaliplatin, manifest important drawbacks often 
leading to treatment failure. Accordingly, new Pt based drugs are still urgently needed. 
These arguments led us to design and investigate some structural analogues of 
established anticancer Pt drugs that have been surprisingly overlooked; specifically, we 
have prepared a few analogues of established Pt drugs through incorporation of non-
conventional halido ligands such as iodide and bromide. We report here on PtI2(DACH), 
an analogue of oxaliplatin that is obtained through the replacement of the oxalate 
ligand with two iodide ligands. The kinetics of activation is significantly influenced by 
oxalate replacement; the biomolecular reactivity is also influenced. In contrast to 
oxaliplatin, PtI2(DACH) is poorly reactive toward model proteins while retaining a 
significant affinity for a representative DNA molecule. The effects of PtI2(DACH) on a 
small panel of CRC cells have been explored as well; PtI2(DACH) similarly to cis-
PtI2(NH3)2 demonstrated an increased capability of inducing apoptosis in the HCT116 
cell line, this cell line being the least sensitive to cisplatin. On the other hand, the 
cytotoxic properties of PtI2(DACH) versus CRC cell lines were roughly comparable to 
those of oxaliplatin. This implies that the presence of the oxalate ligand is not crucial 
for the anticancer activity of oxaliplatin and that the latter may be replaced by other 
ligands such as iodide with nearly full retention of the cytotoxic properties. 
Furthermore, analysis of the proliferation (up to 72 h) of HCT116 cell line treated with 
oxaliplatin and PtI2(DACH) reveal that, even for longer incubation time, differences in 
the cytotoxicity of these two drugs are comparable. This implies that there isn’t any 
“kinetic” of the cytotoxic activity. Remarkably, PtI2(DACH) manifests a larger 
lipophilicity than oxaliplatin and cisplatin. Increased lipophilicity leads to a strong 
enhancement of cellular uptake of this drug in HCT116 cells; however, this enhanced 
uptake does not result in a net enhancement of cytotoxicity possibly in relation to lower 
reactivity. The lower reactivity towards proteins might be associated with a better 
toxicological profile. Overall, we believe that this novel analogue of oxaliplatin 
manifests a number of peculiar chemical and biological features that render it 
particularly attractive and worthy of further preclinical testing in appropriate in vivo 
models of CRC. 
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3. Platinum(II) compounds as promising 
chemotherapeutic agents: further studies on chloride 
and bromide derivatives 
Introduction 
PtI2(DACH) shown to possess a number of peculiar chemical and biological features that 
make it particularly attractive. Despite its solution behaviour was characterized by a 
classical hydrolysis profile with halide release, yet, is scarcely reactive toward model 
proteins being instead highly reactive toward DNA ss oligonucleotides. Notably, we 
found PtI2(DACH) capable to induce cytotoxic effects almost superimposable with those 
of oxaliplatin in representative CRC cell lines being this latter feature accompanied to a 
higher proapoptotic effect than cisplatin and oxaliplatin [1]. In light of these results, 
and in order to further expand the panel of oxaliplatin analogues, we decided to 
prepare and comparatively evaluate two other analogues of oxaliplatin bearing either 
chloride or bromido ligands in place of oxalate i.e. PtCl2(DACH) and PtBr2(DACH). 
Importantly, both these two oxaliplatin derivatives, have been previously synthesized 
and extensively investigated as prospective antineoplastic agents either in vitro and in 
vivo on leukemia, ovarian or sarcoma models; yet, no information are available in 
literature regarding their possible application in the treatment of colorectal cancer 
[2,3a]. It may be stressed that the presence of chlorido or bromide ligands may lead to 
a selective modulation of a few important properties of these compounds, such as the 
respective log P values and the kinetics of ligands release, leading to a different 
biological and pharmacological profile. Also, the comparative analysis allows to 
correlate relevant chemical features with biological and pharmacological effects, that, 
in turn, might allow specific design of more effective complexes for CRC treatment. 
Experimental 
Chemicals and reagents 
Chemicals have been purchased from Sigma-Aldrich and were used without further 
purification. Dodecameric oligonucleotide ODN2 (sequence CTACGGTTTCAC), lysozyme 
(HEWL) and RNase have also been purchased from Sigma-Aldrich. 
Chemistry 
The two reported compounds were synthesized and purified according to literature 
procedures with slight modifications [3].  
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PtCl2(DACH) has been obtained starting from 99,7 mg of K2PtCl4 (2.40x10-4 mol) 
solubilised in 1.5 mL di of milli-Q water. 1,2-diaminocyclohexane (1R,2R)-(–), DACH 
(27.4 mg, 2.42x10-4 mol) was then solubilised in 2 mL of milli-Q water and the obtained 
solution slowly added to K2PtCl4 water solution. After further 4 h of stirring precipitate 
appeared, and complete precipitation of yellow crystals of PtCl2(DACH) allowed over 
night at room temperature. The solid was then collected through vacuum filtration and 
washed with hot water and ice-cooled ethanol and ether. 88.36 mg of PtCl2(DACH) 
were obtained (yield 96%). Complex was characterized through 1HNMR and elemental 
analysis.  
1HNMR (DMF-d7, 400.13 MHz, 298 K): 2.45 (t, J = 8 Hz, 2H); 2.21 (d, J = 12 Hz, 2H); 1.52 
(m, 4H); 1.16 (m, 2H).  
Elemental analysis of C, N and H [calculated C: 18.96%, H: 3.71%, N: 7.37%, 
experimental: C: 18.84%, H: 3.66%, N: 7.30%]. 
For the synthesis of PtBr2(DACH), 99.9 mg of K2PtCl4 (2.41x10-4 mol), have been 
solubilised in 1.5 mL di of milli-Q water. A water solution (2 mL) of KBr (117.7 mg, 
9.64x10-4 mol) was added to K2PtCl4 and stirred (50 °C) in the dark for 5 min until 
quantitative conversion of K2PtCl4 in K2PtBr4 was obtained. 1,2-diaminocyclohexane 
(1R,2R)-(–), DACH (27.2 mg, 2.41x10-4 mol) was then solubilised in 2 mL of milli-Q water 
and the obtained solution slowly added to K2PtBr4 water solution. After further 4 h of 
stirring precipitate appeared, and complete precipitation of yellow crystals of 
PtBr2(DACH) allowed over night at room temperature. The solid was then collected 
through vacuum filtration and washed with hot water and ice-cooled ethanol and 
ether. 79.27 mg of PtBr2(DACH) were obtained (yield 70%). Complex was characterized 
through 1HNMR and elemental analysis.  
1HNMR (DMF-d7, 400.13 MHz, 298 K): 2.50 (t, J = 8 Hz, 2H); 2.23 (d, J = 12 Hz, 2H); 1.56 
(m, 4H); 1.15 (m, 2H).  
Elemental analysis of C, N and H [calculated C: 15.36%, H: 3.01%, N: 5.97%, 
experimental: C: 16.50%, H: 3.14%, N: 6.30%]. 
Uv–Vis experiments 
Solution behavior of PtCl2(DACH) and PtBr2(DACH) was assessed by spectrophotometric 
experiments performed with a Varian Cary 50 Bio UV–Vis spectrophotometer in the 
same condition used in our previous works [1]. 
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LogP value determination 
The octanol-water partition coefficients for PtCl2(DACH) and PtBr2(DACH) was 
determined by modification of reported shake-flask method as reported in our 
previous work [1]. 
ESI-MS experiments 
For comparative purposes ESI-MS spectra of the ODN2-complexes and protein-
complexes mixtures were recorded as already reported in literature [1]. 
Cell culture 
Human colorectal cancer cell lines (HCT-116, HCT-8 and HT29) were cultured in RPMI-
1640 medium (Euroclone; Milan, Italy), supplemented with 2% L-Glut and 10% fetal 
bovine serum (FBS) (complete medium). Human embryonic kidney HEK293 cell line was 
cultured in DMEM medium (Euroclone; Milan, Italy), supplemented with 2% L-Glut and 
10% fetal bovine serum (FBS). 
Cell viability assay 
To evaluate the IC50 of each compound, cell viability was assessed through the Trypan 
Blue exclusion test (Sigma-Aldrich). Cells were seeded at 1x104/well in 96-well plates 
(Costar Corning) in complete medium and incubated for 24 h before compound 
addiction. Following the addition, cells were further incubated for 24 h. Cells were then 
harvested and counted by the Trypan Blue exclusion test using a hemocytometer. All 
experiments were performed in triplicate. The IC50 values were calculated for each cell 
line and data fitted using a Hill1-type equation by using Origin Software (Microcal Origin 
8.0 software; OriginLab Corporation, Northampton, MA). 
Cell cycle analysis 
Cell cycle distribution was assessed by flow cytometry after staining the cells with 
propidium iodide (PI). Cells were seeded and treated generally with different 
compound at their IC50 for 24 h, as already described [1]. 
Results and discussion 
Synthesis and characterization of PtCl2(DACH) and PtBr2(DACH) 
The same synthetic route already exploited for the synthesis of PtI2(DACH), and based 
on modification of existing method [1,4] was used, as reported in more detail in the 
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material and methods section. Both complexes were obtained in good yield and their 
purity assessed through CHN analysis, was found to be higher than 95% (Scheme 1). 
 
Scheme 1: Synthetic route for compounds 1 and 2, respectively. 
LogP value determination 
Octanol-water partition coefficient is an important parameter giving information 
related with the bioavailability and tendency of a compound to cross cell membranes. 
Through the modification of the classical flask-method and as already reported in our 
previous works [2,5a,6], we have determined for PtCl2(DACH) and PtBr2(DACH) a value 
respectively of -0,47 and -0,16. For comparison purposes log P values for a few parent 
Pt complexes are also reported in Table 1 and Table 2. 
 
Table 1: aDetermination of LogP for compound PtCl2(DACH) and PtBr2(DACH) compared 
with cisplatin and oxaliplatin (for comparison purpose Log P for PtI2(DACH) is 0,76**); 
*Ref. [5b], **Ref. [1].  
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Table 2: bIC50 (M) of PtCl2(DACH), PtBr2(DACH), Oxaliplatin and Cisplatin (from top to 
bottom) in HCT-116, HT-29 and HCT-8 CRC cell lines, as well as in an embryonic kidney 
cell line cell line (HEK 293). Cell viability was determined after 24 h of treatment with 
the four different compounds (range 0 – 300 M), by the Trypan Blue exclusion test. 
IC50 values (means ± sem of three independent experiments) were calculated using the 
Origin Software (Microcal Origin 8.0 software; OriginLab Corporation, Northampton, 
MA) fitting experimental data with Hill1 type equation. Remarkably, in line with results 
obtained for cisplatin analogues [5a], PtBr2(DACH) manifests a larger lipophilic 
character than oxaliplatin and in less extent than PtCl2(DACH), whereas shows a lower 
lipophilicity than PtI2(DACH). It is well conceivable that this difference may have some 
appreciable effect in terms of pharmacological activity (Fig. 1). 
 
Fig.1: The two synthesized molecules. 
Solution behaviour 
The solution behaviour of PtCl2(DACH) and PtBr2(DACH) was studied 
spectrophotometrically under physiological-like conditions. Freshly prepared aqueous 
solutions of PtCl2(DACH) and PtBr2(DACH), in 50 mM phosphate buffer, at pH = 7.4, 
manifest a band in the UV–visible region, located around 320 nm, that allows the 
continuous monitoring of the solution behaviour of this platinum complex (Fig. 2).  
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Fig.2: Time course spectra of (a) PtCl2(DACH) and (b) PtBr2(DACH) 10-4M in 50 mM 
phosphate buffer recorded over 72 h, RT. 
After dissolution of the selected compounds in the reference buffer, progressive 
spectral changes are observed, consisting in a decrease of the band centered at 330 nm 
and the appearance of a new band around 280 nm, tentatively assigned to a d–d and a 
LMCT transition, respectively [5a]. These changes, probably are ascribed to the 
progressive release of the two halide ligands [1,5]. The nature of the process and its 
kinetics are similar to what observed in the case of oxaliplatin despite release of halides 
in the case of PtCl2(DACH) and PtBr2(DACH) appears to be slightly faster than in case of 
oxaliplatin and PtI2(DACH) (Fig. 3, Table 3). 
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Table 3: Spectrophotometric determination of Kobs and t1/2 for the hydrolysis reaction 
of 1 and 2 10-4 M in phosphate buffer over 72 h. *The Kobs reported have been 
previously determined in our laboratory [1]. For oxaliplatin Kobs was found to be close 
to that reported in literature by other authors [7]. 
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Fig.3: Experimental kinetic traces and calculated theoretical curve for the hydrolysis of 
the halido derivatives 1 (a) and 2 (b). kobs was calculated fitting with a single exponential 
function (pH value = 7.4). 
Interaction with model biomolecules, ESI-MS experiments 
To investigate the possible interactions occurring between chloride and bromido 
oxaliplatin analogues and their potential biomolecular targets, the two complexes were 
incubated with RNase (Fig. 4) and possible adducts formation was investigated. 
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Fig.4: Deconvoluted ESI-MS spectra of RNase A in 20 mM ammonium acetate buffer, 
pH = 6.8 incubated with PtBr2(DACH) after 24–72 h at 37 °C. The protein concentration 
was 10-4 M (with complex to protein molar ratio of 3:1). *The saline buffer can contain 
small amount of phosphoric acid or sulphuric acid that are responsible of the formation 
of undesired and isobaric adducts with Ribonuclease A (+98 m/z) [8]. 
RNase was chosen since his structure has been often used to characterize the 
interactions occurring between proteins and metallodrugs. These model proteins are 
well suitable for ESI-MS studies, offering a very important substrate for comparative 
mechanistic studies of metal-based drugs. We performed a few ESI-MS experiments 
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where the selected complexes were incubated in 20 mM ammonium acetate buffer, 
pH = 6.8 for increasing time intervals, from 24 to 72 h. ESI-MS spectra recorded for 
RNase in presence of PtBr2(DACH) did not show any signal attributable to the 
metallated protein. The same results were obtained also for PtCl2(DACH). This indicates 
that the two compounds are not able to bind this protein. Also, ESI-MS spectra 
recorded for Lysozyme in presence of PtBr2(DACH) or PtCl2(DACH) did not show any 
signal attributable to the metallated protein. In a previous study, similar results were 
obtained for PtI2(DACH) [1]. Conversely, in other works, some of us have shown 
significant interactions between oxaliplatin and the two selected model proteins [9,10]. 
We hypothesized that an explanation for this different behaviour could be that 
coordination of oxaliplatin to lysozyme and RNase implies a multi-step reaction at the 
level of aspartate residues. This implies, at first a non-covalent coordination of 
oxaliplatin to the protein; then detachment of one oxygen atom of oxalate from Pt 
coordination with a ring-opening step leading to monodentate oxalate, with 
concomitant Pt coordination of the carboxylate group from an aspartate residue. 
Finally, the complete release of the oxalate ligand [4,6]. The replacement of the oxalate 
with the halide ligands could cause loss of the first non-covalent interaction, which 
could be an important step in the reactivity of oxaliplatin with these proteins. 
Binding with model oligonucleotide: ESI-MS experiments 
It is generally accepted that the distortion of DNA generated upon binding of cisplatin 
and oxaliplatin is largely responsible for their antitumor properties [11]. Subsequent 
drug activation via intracellular aquation reactions results in a variety of stable 
bifunctional DNA–platinum(II) adducts. 1,2-Intrastrand cross-links between two 
adjacent guanine bases d(GG) or between an adenine and a guanine residue d(AG) are 
primarily formed. The platinum centre of complexes, with a cis motif, preferentially 
coordinates to the N7 position of both adenine and guanine in the major groove of DNA 
[12]. For these reasons we tested the binding properties of the three oxaliplatin 
analogues with a simplified oligonucleotide model bearing the characteristic GG motif. 
The selected complexes interact extensively with the tested oligonucleotide bearing 
the GG motif (ODN2) through a classical reaction pattern involving preferential release 
of halide ligands (Fig. 5) [13]. PtBr2(DACH), in this case, shows a greater reactivity 
compared to PtCl2(DACH) and PtI2(DACH), as highlights the ESI-MS spectrum in Fig. 5, 
in which the peak of native ODN2 completely disappeared after adduct formation. 
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Fig.5: Deconvoluted ESI-MS spectra of ODN2 in Milli-Q water incubated with 
PtCl2(DACH) and PtBr2(DACH) after 72 h at 37 °C. The oligonucleotide concentration 
was 10-4 M (with complex to oligonucleotide molar ratio of 2:1). 
Biological effects 
The cytotoxic effects of PtCl2(DACH) and PtBr2(DACH) were then investigated in three 
CRC cell lines (HCT-116, HCT-8 and HT-29) in comparison with cisplatin and oxaliplatin. 
A normal cell line (HEK 293 cells) was also included. Cells were exposed to increasing 
concentrations of the drugs for 24 h, and the respective IC50 concentrations were 
determined by the Trypan blue exclusion test. As reported in Table 2, PtBr2(DACH) and 
in particular PtCl2(DACH), in comparison to oxaliplatin, show a greater cytotoxic effect 
only on the cell line least sensitive to cisplatin (i.e. HCT- 116) being less effective in the 
other cancer lines. The PtX2(DACH) series conserves appreciable cytotoxic properties 
and is roughly similar to oxaliplatin. This implies that replacement of oxalate with two 
halido ligands does not impair the cellular effects of this drug. Additionally, when 
evaluating the effects of all compounds on embryonic kidney cell line HEK293, we can 
assert that the cytotoxicity is overall similar and rather low, being the PtCl2(DACH) 
significantly less cytotoxic. Based on these results we studied the effects that 
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PtCl2(DACH) and PtBr2(DACH) (tested at their respective IC50s) produce on HCT-116 
cells, determining the distribution of the cells in the various phases of the cell cycle. 
These effects were measured in the absence or in the presence of the four compounds 
tested at their respective IC50s. Preliminary results evidenced that as already reported 
for cisplatin, oxaliplatin and its iodido analogue [5b], PtCl2(DACH) and PtBr2(DACH) 
caused a variation of cell cycle distribution of HCT-116 cells (Table 4 and Fig. 6), with a 
block in G2/M phase. The same effect has been found also in HCT-8 cells (Fig.7). 
 
Table 4: Cell cycle distribution of HCT-116 cells after 24 h of treatment with PtCl2(DACH) 
and PtBr2(DACH) at the IC50 values shown in Table 2. Data are means ± sem of four 
independent experiments, and are expressed as percentage of cells in each phase of 
the cell cycle, determined by flow cytometry after staining the cells with propidium 
iodide (PI). 
 
Fig.6: Cell cycle distribution of HCT-116 cells after 24 h of treatment with PtBr2(DACH) 
and PtCl2(DACH) at the IC50 values. Representative histograms of data reported in 
Table 4. 
 43 
 
 
Fig.7: Cell cycle distribution of HCT-8 cells after 24 h of treatment with PtBr2(DACH) 
and PtCl2(DACH) at the IC50 values. 
Conclusion 
Colorectal cancer is a global health problem being the fourth most common cause of 
death due to cancer worldwide. Oxaliplatin plays a key role in current CRC treatment 
but shows serious drawbacks, such as a high systemic toxicity and the frequent 
insurgence of Pt resistance. This work continues a research line started a few years ago 
that is based on the idea that small modifications in the scaffold of established 
anticancer Pt drugs may lead to significant and hopefully positive changes in their 
pharmacological profile with appreciable effects in the overall spectrum of anticancer 
actions and in the ability to overcome Pt resistance in CRC. The exchange of halide 
ligands (e.g. replacement of chloride with iodide in cisplatin) represents indeed a small 
structural change with a relevant chemical and biological impact. Specifically, we have 
prepared here two analogues of oxaliplatin through incorporation of non-conventional 
halido ligands such as chloride and bromide. From the inspection of the solution 
behaviour, we have observed hydrolysis profiles similar to oxaliplatin, with a release of 
the halido ligand faster for chloride than bromide or iodide. At variance from oxaliplatin 
and in line with PtI2(DACH), the selected compounds showed a scarce reactivity 
towards model proteins, while keeping affinity for a standard DNA oligo. These findings 
are of considerable interest; in fact, despite DNA is recognized as the main target for 
Pt-based anticancer agents, protein binding is nowadays considered a key aspect for 
the pharmacological profile. Interaction with aminoacidic residues of proteins may 
have a primary role in the pharmacokinetic and bioavailability of metal-based 
antineoplastic compounds. Also, the coordination of metal center to specific protein 
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sites, may result in an inhibition and damage of enzymes, leading in turn to augmented 
side effects [14]. Thus, the lack of reaction of the study compounds when reacted with 
model protein targets, and the concomitant conserved reactivity toward 
oligonucleotides may have important biological consequences. Furthermore, we have 
shown that CRC cells that were treated with PtCl2(DACH) and PtBr2(DACH) manifest at 
24 h a clear spike in the G2/M fraction; the cytotoxic properties versus CRC cell lines of 
the two study compounds were roughly comparable to those of oxaliplatin. This implies 
that the presence of the oxalate ligand is not crucial for the anticancer activity of 
oxaliplatin and that the latter may be replaced by halido ligands with nearly full 
retention of the cytotoxic properties. Results collected indicated that treatments with 
PtCl2(DACH) and PtBr2(DACH) affect growth of human CRC cells and induce an evident 
cell cycle arrest ultimately triggering cellular apoptosis. Overall, a rather interesting 
picture emerges for these novel Pt drugs that merit, in our opinion, a deeper and more 
extensive preclinical evaluation. 
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4. Gold(I) and Silver(I) compounds and their antibacterial 
properties 
Introduction 
Several metals and metal-based compounds have been used for centuries as anti-
infective agents on a simple empirical basis, with some appreciable results. For 
instance, the complex dicyanoaurate(I) was proposed and used by Koch as an 
antitubercular agent during the pioneering times of modern pharmacology, and several 
bismuth, antimony and mercury compounds have been extensively used to combat 
various bacterial and parasitic diseases [1–4]. However, more recently, due to the 
advent of the golden era of antibiotics and owing to justified concerns about their 
systemic toxicity, metal-based agents have been gradually abandoned. Only a few 
exceptions remain in the clinic for specific therapeutic indications, such as bismuth salts 
for the eradication of Helicobacter pylori infection, and antimony compounds as 
antileishmanial agents [3, 5]. However, during the last two decades, the so-called 
“antibiotic resistance crisis”—arising from the emergence of bacterial strains with 
multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes, and from 
the simultaneous decline in the discovery rate of new and effective antibiotic 
molecules— has posed the dramatic problem of finding new substances capable of 
fighting life-threatening infections caused by these pathogens [6, 7]. Metal-based 
compounds are thus being reconsidered as a rich source of antimicrobial agents often 
having novel modes of action. In this context, Auranofin (AF), an antiarthritic agent still 
sporadically used to treat some severe forms of rheumatoid arthritis, has been revisited 
within the framework of drug repurposing strategies, with rather promising results. 
Indeed, remarkable antimicrobial and antiparasitic properties have been reported for 
this oral gold(I) drug, which has become the reference compound for the development 
of novel gold-based antibacterial agents or specific inhibitors of important enzymes [7, 
8]. Some recent studies investigated in detail the mechanistic aspects of its 
antimicrobial action. It was shown that AF probably acts through a multifactorial and 
multitarget mechanism and that the low susceptibility of Gram-negative bacteria to this 
drug is probably the consequence of reduced intracellular gold accumulation [9–12]. 
However, the precise mechanisms of the antimicrobial action of AF, and the respective 
biomolecular targets, are not known. The promising antibacterial properties reported 
for AF prompted us to test not only AF but also a series of related metal complexes, 
prepared in our laboratory, against a panel of isolates, including major Gram-positive, 
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Gram-negative and fungal pathogens showing relevant resistance phenotypes. Due to 
the so-called “antibiotic resistance crisis” new antibacterial agents are urgently sought 
to treat multidrug-resistant pathogens. A group of gold- or silver-based complexes, of 
general formula [M(PEt3)X] (with M=Au or Ag, and X=Cl, Br or I), alongside with three 
complexes bearing a positive or negative charge—[Au(PEt3)2]Cl, K[Au(CN)2] and 
[Ag(PEt3)2]NO3—were prepared and comparatively tested with AF on a representative 
panel of pathogens including Gram-positive, Gram-negative and Candida strains. 
Interestingly, all the gold and silver complexes tested were active on Gram-positive 
strains, with the gold complexes having greater efficacy. The effects of the gold 
compounds were potentiated to a larger extent than silver compounds when tested in 
combination with a permeabilizing agent. A number of relevant structure–activity 
relationships emerged from the comparative analysis of the observed antibacterial 
profiles, shedding new light on the underlying molecular mechanisms of the action of 
these compounds. Some classical gold complexes were also prepared and evaluated. 
We postulated that a comparative analysis of the antimicrobial behaviour of the various 
structurally related gold(I) and silver(I) complexes might provide valuable mechanistic 
insight on the activity of AF and its derivatives, and perhaps lead to drug improvement 
through chemical modification as well as to a better understanding of the observed 
pharmacological effects.  
Results and Discussion 
The panel of studied gold and silver compounds is shown in Figure 1. For gold-based 
complexes the panel includes, as well as AF, three gold complexes of general formula 
[Au(PEt3)X] where X is a halide ligand; these latter compounds are known AF analogues 
in which the thiosugar ligand is replaced by chlorido, bromido or iodido ligand [13]. The 
cationic diphosphino gold(I) and the anionic dicyanoaurate(I) complexes, prepared 
according to reported procedures, were also included in the panel of test compounds 
(see the Experimental Section for details on their synthesis, CHN analysis, NMR and 
UV/Vis spectroscopic characterization) [14]. Careful analysis of the obtained results 
provides valuable insight on structure–activity relationships. Consistent with 
expectations, AF showed similar antimicrobial activity against all tested Gram-positive 
species, with the exception that it was poorly active against Candida albicans (Table 1). 
It is interesting to compare the behaviour of the [Au(PEt3)X] compounds with AF. 
Remarkably, the [Au(PEt3)X] complexes exhibit antimicrobial properties against Gram-
positive bacteria, with a potency that is similar to or slightly lower than AF. Also, the 
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antibacterial profiles of the three [Au(PEt3)X] complexes against these pathogens are 
similar to one another, being almost superimposable.  
 
Fig.1: The panel of investigated gold and silver complexes. For clarity, the structure of 
the neutral silver complex, has been here reported in a simplified manner; those 
species are tetrameric with a structure of the type [Ag(PEt3)X]4. 
These observations imply that the thiosugar ligand is not essential for the antimicrobial 
activity of AF. Similarly, the nature of the X ligand seems to play a minor role, if any, in 
determining the antimicrobial profiles of the three [Au(PEt3)X] compounds, which are 
nearly identical. Altogether, these results point to the [Au(PEt3)]+ moiety as the “true 
pharmacophore”. The strong similarity in the antimicrobial activity of the three 
[Au(PEt3)X] complexes also suggests that their uptake is similar. Similarly to AF, the 
three [Au(PEt3)X] compounds were less active against C. albicans.  
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To expand our analysis of structure–activity relationships, the two charged gold(I) 
compounds were then evaluated. Interestingly, the cationic diphosphine complex 
exhibited important antimicrobial properties similar to those of [Au(PEt3)X] complexes. 
Again, this suggests that a single phosphine ligand is sufficient for the biological activity. 
In contrast, the dicyano gold(I) complex resulted much less active than [Au(PEt3)2]Cl. 
This observation might imply either that the negatively charged dicyano gold(I) complex 
is taken up less efficiently than neutral or positive gold complexes, or that the cyanide 
ligand is so strong that the biological action of the gold(I) center—probably linked to 
gold(I) coordination to a specific biomolecular target—is greatly inhibited. In 
considering this latter aspect, it is worth comparing the antimicrobial properties of two 
carbene complexes with the structures R-Au-R and R-Au-Cl (R= 1,3-Dimethylimidazol-
2-ylidene)  (Figure 2) that we tested previously on different bacterial strains 
(unpublished results: see the Table 2 for MIC values).  
 
Fig.2: Structures of the two carbene gold compounds. 
 
 S. aureus ATCC 25923 
Au(NHC)Cl 0.5 
Au(NHC)2PF6 8 
 
Tab.2: MIC (g/mL) values obtained for carbene gold compounds. 
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We observed that the dicarbene complex was far less active than the monocarbene on 
a Gram-positive strain (Staphylococcus aureus ATCC 2592). This lower activity is likely 
related to the greater stability of the R-Au-R Complexes [15, 16]. Conversely, the 
greater antimicrobial effects of the monocarbene gold complex, where Cl- is a labile 
ligand, seems to support—at least indirectly—that its biological activity is linked to the 
ease of ligand displacement and to consequent gold coordination to relevant biological 
targets. As previously reported, AF is scarcely active on Gram-negative strains; this is 
tentatively attributed to reduced drug uptake [10]. To confirm these findings and assess 
whether such limited activity of gold compounds in Gram-negative bacteria is 
“conserved” upon replacement of a thiosugar with different ligands, we investigated 
the antibacterial effects of the experimental drugs on five Gram-negative strains of 
clinical origin. Also, to further understand the underlying mechanistic aspects of the 
activity, we repeated the same experiments on Gram-negative isolates in the presence 
of the permeabilizing agent polymyxin B nonapeptide (PMBN). The MIC values are 
summarized in Table 3.  
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According to data reported in the literature, AF is poorly active against Gram-negative 
bacterial strains [10]. Although in general [Au(PEt3)X] analogues, similarly to 
[Au(PEt3)2]Cl, show slightly greater activity than AF toward the six Gram-negative 
strains, their potency is still significantly lower than in Gram-positive isolates. The 
dicyano gold(I) complex was again the least active of the panel. However, if these gold 
compounds were administered in combination with the permeabilizing agent PMBN, a 
marked increase of the antibacterial effects was observed for AF and the [Au(PEt3)X] 
series, as well as for [Au(PEt3)2]Cl, confirming that the difficulties in gold uptake 
reported for AF also arise with [Au(PEt3)X] complexes. No significant increase of the 
antibacterial effects of K[Au(CN)2] was observed in the presence of PMBN. This might 
offer indirect confirmation that the strong coordination of the cyanide ligand to the 
gold(I) center accounts for the weak antibacterial effects due to lack of ligand 
dissociation and of gold binding to bacterial targets. Interestingly, the MIC values 
determined for Pseudomonas aeruginosa Vr143/97 (strain 17) decreased markedly for 
all compounds if tested in the presence of PMBN, including the anionic dicyanide 
complex; this strong effect probably arises from the reported intrinsic higher 
susceptibility of this strain to PMBN [17]. Notably, a smaller decrease of MIC values in 
the presence of PMBN was observed for some compounds (e.g. AF and [Au(PEt3)X]) for 
Klebsiella pneumoniae KKBO4 (strain 16); this strain shows a resistant phenotype to 
polymyxins (Table 3) owing to an alteration of the outer membrane lipopolysaccharide, 
that is also likely responsible for the lower susceptibility of this strain to the 
permeabilizing action of PMBN [18]. The above results and their implications prompted 
us to prepare a second set of compounds, strictly related to the gold panel, consisting 
of four distinct silver(I) complexes (Figure 1). The three silver compounds, of general 
formula [Ag(PEt3)X], and the diphosphine cationic complex were prepared and 
characterized, as reported in the Experimental Section and in the Supporting 
Information. [Ag(PEt3)X] complexes have been known for decades; studies carried out 
by Churchill et al. indicated that in the solid state these complexes possess a 
[Ag(PEt3)X]4 “cubane-like” skeleton of alternating silver and halogen [19]. By analogy 
with gold compounds, the solution behaviour of the silver complexes was assessed by 
NMR spectroscopy in dimethyl sulfoxide, phosphate-buffered saline (PBS) and in the 
presence of the media used for the biological experiments (details and spectra are 
reported in the Supporting Information). The studied complexes were highly stable 
both in organic solvents and in PBS. It should be noted that the 31PNMR spectral 
linewidths of the silver complexes are larger than those of the corresponding gold 
complexes, this being an indication for the rapid equilibria that characterize silver 
compounds in solution and for a greater lability of ligands in the case of silver 
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complexes compared with gold ones. In addition, no evidence of 31P–107/109Ag coupling 
was found in our experimental conditions (i.e. at room temperature), which was further 
confirmation of the above interpretation [20]. Interestingly, if incubations were made 
in the Mueller–Hinton (MH) broth (the medium used for MIC determination), the 
31PNMR peaks converge toward a chemical shift of 37.20 ppm, indicating the formation 
of the same chemical species. This observation supports the view that silver 
compounds, in the presence of a high concentration of peptides and amino acids in the 
broth, rapidly react leading to the same species likely originating from the coordination 
of amino acid residues to the silver center. No evidence for precipitation was found in 
the experimental conditions used. From comparative analysis of the obtained results it 
is evident that silver compounds are less effective than gold compounds; this means 
that replacement of gold(I) with silver(I) results in a general decrease of the 
antibacterial potency (Table 4). This finding might be rather surprising in light of the 
well-known antimicrobial properties of silver compounds. However, the lower stability 
of the silver complexes in the biological medium revealed by the NMR experiments 
might account for this net decrease in biological effects. Also, it was observed that MIC 
values are similar for the [Ag(PEt3)X] series, with the exception of the cationic complex 
[Ag(PEt3)2]NO3 for which the values are significantly larger.  
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This result can be explained by considering the nature of the ligands and the relative 
stability in the biological medium. Indeed, through comparative evaluation of the 
31PNMR spectra, it appears that after 72 h of incubation, complexes of the type 
[Ag(PEt3)X] undergo quantitative conversion leading to the appearance of the same 
multiplet signal at 37.20 ppm, assignable to a species in which the halide ligands (or 
phosphine, to a minor extent), are replaced by sulfur or other coordinative atoms 
belonging to protein/peptides chains [20]. In Figure 3 are reported the spectra of 
Ag(PEt3)Cl acquired at t0 and after 72 h of incubation (Ag(PEt3)Br and Ag(PEt3)I show 
similar behaviour), in which is possible to observe the decreasing of the signal of 
Ag(PEt3)Cl (10.51 ppm) with the rising of the specie at 37.20 ppm and a small formation 
of triethylphosphine oxide (peak at 61 ppm). On the contrary, for solutions of 
[Ag(PEt3)2]NO3 incubated for 72 h, the peak assigned to the original species at 9.93 ppm 
is still strongly detected alongside the signal at 37.20 ppm (Figure 4). In this case, the 
peak assignable to triethylphosphine oxide (61 ppm) is clearly detectable even at t0. 
Thus, even for the silver cationic complex, a ligand displacement process is likely to 
occur, that produces the same species as in the case of [Ag(PEt3)X] compounds, with 
concomitant release of one triethylphosphine ligand that is oxidized to the 
corresponding oxide. However, in this latter case, the process is much slower. Next, the 
effects of silver compounds on the Gram-negative strains were studied (Table 5). The 
MIC values determined in Gram-negative strains, consistent with the findings on 
stability, reveal that all silver compounds exhibit similar antibacterial effects. Even in 
this case, the lowest activity was observed for the cationic complex. Interestingly, in 
contrast with the results obtained with the gold compounds (Table 3), for which a 
strong enhancement of the antibacterial effects was evident, the activity of the silver 
compounds in Gram-negative bacteria was weakly affected by pre-treatment with the 
permeabilizing agent. Again, this finding might reflect the chemical transformations of 
the silver complexes that occur in the biological medium. 
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Fig.3: 31PNMR analysis of Ag(PEt3)Cl (161.97 MHz, 298 K). Acquisition performed in a 
mixture of 250 μL MH Broth, 650 μL CH3OH and 200 μL CD3OD. The spectra were 
acquired at t0 (blue) and after 72 h (red).  
 
 
Fig.4: 31PNMR analysis of [Ag(PEt3)2]NO3 (161.97 MHz, 298 K). Acquisition performed in 
a mixture of 250 μL MH Broth, 650 μL CH3OH and 200 μL CD3OD. The spectra were 
acquired at t0 (blue) and after 72 h (red).  
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Conclusions 
We have analysed the stability profiles in different conditions (organic solvent, PBS, 
biological media) and the antimicrobial properties on clinical isolates of a small group 
of neutral gold(I) or silver(I) complexes of the type [M(PEt3)X] (M=metal, X=halide), as 
well as of selected complexes bearing a positive or negative charge, that is, 
[Au(PEt3)2]Cl, K[Au(CN)2] and [Ag(PEt3)2]NO3. Comparative analysis of the results 
allowed us to define the following structure–activity relationships: 
1. The thiosugar ligand is not essential for the antimicrobial activity of AF and 
apparently does not favor an increased gold uptake. 
2. The identity of the X ligand in the [Au(PEt3)X] series is not relevant for the activity; 
similar antimicrobial profiles were seen observed for the three homologous complexes. 
3. The gold–diphosphine cationic complex is as active as the [Au(PEt3)X] derivatives, 
implying that the positive charge and the presence of two phosphine ligands are not 
functionally relevant features. 
4. Altogether, the above results indicate the [Au(PEt3)]+ moiety as the “true 
pharmacophore” in this series of metal complexes; their antimicrobial activity probably 
arises from gold coordination to appropriate targets after ligand exchange. 
5. The anionic [Au(CN)2]- complex showed strongly reduced activity: this might be the 
consequence of the greater stability of the cyanide–gold bond. 
6. Replacement of gold(I) with silver(I) causes a net reduction in the measured 
antimicrobial activity. This might be the consequence of the rather large instability of 
these complexes clearly detected in the MH broth. Alternatively, the observed 
reduction in antimicrobial effects might be due to a reduced ability of silver(I) to inhibit 
bacterial targets. 
7. The susceptibility of Gram-negative strains to gold compounds is increased in the 
presence of a permeabilizing agent (PMBN), indicating that one of the mechanisms of 
resistance to these compounds in such pathogens is their reduced uptake. 
8. Among the various possible protein targets, in analogy with the case of auranofin, 
thioredoxin reductase might represent a likely target even for the gold and silver 
analogues [21]. 
Thus, we have shown here that comparative analysis of the respective antimicrobial 
profiles is a valid tool for selecting the “best performers” to be further evaluated as 
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innovative and more efficient antimicrobial metal-based drugs. Hints were obtained 
toward deciphering the mechanism of action and designing better metal-based 
antimicrobial agents and drug combinations. 
Experimental Section 
Chemicals and reagents 
Chemicals and reagents were purchased and used without further purification. 
Auranofin was obtained from Vinci-Biochem (Vinci, Italy). 
Chloro(triethylphosphine)gold(I) was purchased from Sigma–Aldrich. 
NMR analysis 
NMR experiments were performed on a Bruker Ultrashield 400 spectrometer. 
Calibration was made according to the residual peak of the solvent. Raw data were 
analyzed using Topspin software (Bruker). Spectra are available in the Supporting 
Information. 
UV/Vis analysis 
The spectrophotometric analysis of K[Au(CN)2] was performed on a Varian Cary 50 Bio 
UV/Vis spectrophotometer. 
MIC value determination 
MICs were determined using a standard broth microdilution assay on 96-well plates, as 
recommended by the Clinical and Laboratory Standards Institute [22]. Assays were 
performed in triplicate using cation-supplemented MH broth (Becton Dickinson, 
Franklin Lakes, NJ) and a bacterial inoculum of 5V104 CFU per well, in a final volume of 
100 mL. AF and [Au(PEt3)X] and [Ag(PEt3)X] compounds were initially dissolved in DMSO 
and then diluted to the test concentrations in MH broth. Cationic diphosphine and 
anionic dicyano compounds were initially dissolved in sterile doubly distilled water and 
then diluted as described above. Results were recorded after 18–20h of incubation at 
37 °C. For Gram-positive strains, the tested concentrations ranged from 0.062 to 8 
mg/mL for all the substances. MICs for Gram-negatives for the tested compounds, 
alone or in the presence of the permeabilizing agent PMBN, were determined as 
described above for Gram-positive strains according to the Clinical and Laboratory 
Standards Institute. PMBN was used at a final concentration of 25 mg/mL [23]. For 
these strains, AF, [Au(PEt3)2]Cl and K[Au(CN)2] were tested at concentrations from 0.25 
to 32 mg/mL, whereas the other substances were tested at concentrations from 0.062 
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to 8 mg/mL. MICs were determined for all strains and compounds in at least three 
separate experiments. Main resistance phenotypes of the tested strains are shown in 
Tables 1–4. 
Synthesis 
[Au(PEt3)Br]. According to a modified reported method [24], [Au(PEt3)Cl] (48.6 mg) was 
stirred in N,N-dimethylformamide (3 mL) with KBr (5 equiv) at RT. After 18 h the mixture 
was dried under vacuum and the resulting solid was re-dissolved in a mixture of 
dichloromethane (10 mL) and demineralized H2O (10 mL). The mixture was transferred 
into a separation funnel and more demineralized H2O (10 mL) was added. After 
separation, the aqueous phase was again extracted with dichloromethane (10 mL). The 
recombined organic phase was then washed with saturated NaCl solution (20 mL), 
dried with Na2SO4, filtered and evaporated under reduced pressure. The crude product 
was re-dissolved in chloroform (3 mL), then diethyl ether (7 mL) and hexane (20 mL) 
were added. The flask was kept at -20 °C for 96 h to allow crystals to grow. Yield 73.6% 
(40.1 mg).  
1HNMR (CD3OD, 400.13 MHz, 298 K): = 1.943 (dq, JHH= 7.64 Hz, JHP= 10.48 Hz, 6H), 
1.215 (dt, JHH= 7.60 Hz, JHP= 19.12 Hz, 9H) ppm;  
13CNMR (CD3OD, 100.61 MHz, 298 K): = 19.04 (d, JCP= 36.45 Hz), 9.44 ppm;  
31PNMR (CD3OD, 161.97 MHz, 298 K): = 36.38 ppm;  
elemental analysis calcd (%) for C6H15AuBrP: C 18.24, H 3.83; found: C 18.36, H 3.55. 
Au(PEt3)I. [Au(PEt3)Cl] (40 mg) was stirred in ethanol with KI (5 equiv) at RT. After 3 h, 
the mixture was dried under vacuum and the resulting white solid was kept at -20°C 
overnight. The product was then extracted five times with dichloromethane (3 mL). The 
recombined organic phase was washed three times with water (3 mL) and dried with 
MgSO4. The solvent was evaporated under vacuum to a final volume of 3 mL, and the 
product was precipitated by addition of pentane (50 mL). After filtration, the white 
product was dried under vacuum overnight. Yield 70%.  
1HNMR (CD3OD, 400.13 MHz, 298 K): = 1.955 (dq, JHH= 7.68 Hz, JHP= 10.44 Hz, 6H), 
1.235 (dt, JHH= 7.60 Hz, JHP =19.12 Hz, 9H) ppm; 
13CNMR (CD3OD, 100.61 MHz, 298 K): = 19.20 (d, JCP= 34.55 Hz), 9.27 ppm;  
31PNMR (CD3OD, 161.97 MHz, 298 K): = 41.17 ppm;  
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elemental analysis calcd (%) for C6H15AuIP: C 16.30, H 3.21; found: C 16.01, H 3.21, calcd 
H: 3.42. 
[Au(PEt3)2]Cl. [Au(PEt3)Cl] (40 mg) was stirred at RT and under inert conditions (Schlenk 
technique) with a solution of triethylphosphine in tetrahydrofuran (1M, 1 mL, 10 
equiv). After 3 h, stirring was stopped and the reaction mixture was kept under a flow 
of nitrogen overnight to evaporate both tetrahydrofuran and unreacted 
triethylphosphine. After evaporation, the product was recovered in the form of large 
colorless crystals. The crude product was dried under reduced pressure to remove all 
traces of unreacted materials. Yield 77 %.  
1HNMR (CD3OD, 400.13 MHz, 298 K): = 2.055 (q, JHH= 7.64 Hz, 12H), 1.264 (br s, 18H) 
ppm;  
13CNMR (CD3OD, 100.61 MHz, 298 K): = 19.20 (br), 9.43 ppm;  
31PNMR (CD3OD, 161.97 MHz, 298 K): = 47.83 ppm;  
elemental analysis calcd (%) for C12H30AuClP2: C 30.75, H 6.45; found: C 31.28, H 6.25. 
K[Au(CN)2]. WARNING: SOME STEPS IN THIS PROCEDURE INVOLVE THE FORMATION OF 
FULMINATING GOLD (EXPLOSIVE MATERIAL) AND USE OF KCN (HIGHLY TOXIC). 
According to a modified reported method [25], a solution of HAuCl4 (1 M, 2.5 mL) was 
stirred in a beaker with aqueous NH3 (3 M, 10 mL). The resulting suspension was gently 
warmed (at about 60 °C) for 3 h. The fulminating gold that formed was carefully filtered 
using a Buchner funnel and washed well with distilled water. To minimize the risk of 
explosions, in this step the fulminating gold was kept wet. The moist product was 
transferred into a beaker with the filter and distilled water (20 mL) was added. The 
suspension was stirred at RT, KCN (350 mg, 2.15 equiv) was added and the mixture 
turned quickly into a clear pale red solution. The white crystalline product was 
precipitated by evaporation by gently heating the solution with stirring. The crude 
product was then washed in a Buchner funnel with ethanol (2 mL) and dried under 
reduced pressure. Yield: 252.6 mg (35.1 %). 
13CNMR (D2O, 100.61 MHz, 298 K): = 154.97 ppm;  
UV/Vis: (10-4M in PBS, pH 7.4): max=205, 212, 230, 240 nm;  
Elemental analysis calcd (%) for C2AuKN2: C 8.34, N 9.72; found: C 8.46, N 9.88. 
[Ag(PEt3)Cl]. Under inert conditions, AgCl (200 mg) was added to a solution of PEt3 in 
tetrahydrofuran (1M, 1.1 mL, 0.8 equiv). The heterogeneous mixture was stirred at RT 
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for 4 h, then the liquid phase was evaporated under reduced pressure. The crude 
product was suspended in dichloromethane (5 mL) and the solid was filtered off. The 
liquid phase was evaporated to afford the pure product (260 mg, 71.6 %).  
1HNMR (CD3OD, 400.13 MHz, 298 K): = 1.764 (m, 6H), 1.193 (dt, JHH= 7.66 Hz, JHP= 17.96 
Hz, 9H) ppm;  
13CNMR (CD3OD, 100.61 MHz, 298 K): = 18.07 (d, JCP= 18.70 Hz), 9.76 ppm; 
31PNMR (CD3OD; 161.97 MHz, 298 K): = 8.83 ppm;  
elemental analysis calcd (%) for C6H15AgClP: C 27.56, H 5.78; found: C 27.93, H 5.82. 
[Ag(PEt3)Br]. Under inert conditions, AgBr (300 mg) was added to a solution of PEt3 in 
tetrahydrofuran (1M, 1.2 mL, 0.8 equiv). The heterogeneous mixture was stirred at RT 
for 3 h, then the liquid phase was evaporated under reduced pressure. The crude 
product was suspended in dichloromethane (5 mL) and the solid was filtered off. The 
liquid phase was evaporated to afford the pure product (380 mg, 77.8 %).  
1HNMR (CD3OD, 400.13 MHz, 298 K): = 1.747 (m, 6H), 1.193 (dt, JHH= 7.65 Hz, JHP= 17.73 
Hz, 9H) ppm; 
13CNMR (CD3OD, 100.61 MHz, 298 K): = 18.19 (br), 9.71 ppm; 
31PNMR (CD3OD; 161.97 MHz, 298 K): = 6.68 ppm;  
elemental analysis calcd (%) for C6H15AgBrP: C 23.56, H 4.94; found: C 23.73, H 5.33. 
[Ag(PEt3)I]. Under inert conditions, AgI (260 mg) was added to a solution of PEt3 in 
tetrahydrofuran (1M, 0.9 mL, 0.8 equiv). The heterogeneous mixture was stirred at RT 
for 1.5 h, then the liquid phase was evaporated under reduced pressure. The crude 
product was suspended in dichloromethane (5 mL) and the solid was filtered off. The 
liquid phase was evaporated to afford the pure product (270 mg, 79.7 %).  
1HNMR (CDCl3, 400.13 MHz, 298 K): = 1.664 (m, 6H), 1.169 (dt, JHH= 7.99 Hz, JHP= 15.98 
Hz, 9H) ppm;  
13CNMR (CDCl3, 100.61 MHz, 298 K): = 18.53 (d, JCP= 12.74 Hz), 10.39 ppm; 
31PNMR (CDCl3; 161.97 MHz, 298 K): = -8.39 ppm;  
Elemental analysis calcd (%) for C6H15AgIP: C 20.42, H 4.28; found: C 20.51, H 4.36. 
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[Ag(PEt3)2]NO3. Under inert conditions, AgNO3 (162.1 mg) was added to a solution of 
PEt3 in tetrahydrofuran (1M, 1.9 mL, 2 equiv). After a few seconds the solid was totally 
dissolved. The solution was stirred at RT for 2 h, then the solvent and the unreacted 
phosphine were removed under reduced pressure to give a viscous liquid (335.2 mg, 
86.5 %).  
1HNMR (CD3OD, 400.13 MHz, 298 K): = 1.787 (m, 12 H), 1.190 (br s, 18H) ppm;  
13CNMR (CD3OD, 100.61 MHz, 298 K): = 17.85 (d, JCP=12.55 Hz), 9.72 ppm;  
31PNMR (CD3OD; 161.97 MHz, 298 K): = 8.49 ppm;  
elemental analysis calcd (%) for C12H30AgNO3P2: C 35.48, H 7.44, N 3.45; found: C 35.79, 
H 7.47, N 3.30. 
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5. Gold(I) compounds as promising chemotherapeutic 
agents 
Introduction 
Auranofin [2,3,4,6-tetra-o-acetyl-L-thio-β-D-glyco-pyranosato-S-(triethyl- phosphine)-
gold(I)] (AF) is a clinically established oral chrysotherapeutic agent that is used for the 
treatment of some severe forms of rheumatoid arthritis [1]. During the past few years, 
this drug has attracted renewed attention in the medicinal chemistry scientific 
community as a prospective anticancer and antimicrobial agent according to innovative 
drug repurposing strategies [2−4]. In particular, AF has been, or still is, the object of 
clinical trials in the US as an anticancer agent [5,6]. We thought that selective and 
limited chemical modifications of AF might lead to a modulation and hopefully an 
improvement of its pharmacological profile. To this regard, it is worth reminding that 
Frank Shaw, on the ground of similar arguments, prepared and characterized a few 
years ago seleno-auranofin, a derivative of auranofin where the thiosugar ligand is 
replaced by the corresponding selenosugar ligand, and obtained remarkable biological 
results [7]. Accordingly, we decided to prepare a derivative of AF where the thiosugar 
ligand is replaced by one iodide ligand and to test this compound in comparison to AF 
and its commercially available chloride analogue. In principle, replacement of the 
thiosugar or chloride ligand with iodide should afford a compound of increased 
lipophilicity, thus enhancing drug bioavailability; at the same time, substitution of such 
a large ligand as thioglucose tetraacetate with a monatomic ligand, i.e., iodide, should 
not affect substantially the drug’s pharmacological profile as the thiosugar ligand is 
believed to act mainly as a carrier ligand and, also, as a good leaving group, while the 
[Au(PEt3)]+ moiety is assumed to be the “true pharmacophore”. In nice agreement with 
this view, previous studies showed that Au(PEt3)Cl manifests biological properties 
similar though not identical to those of AF [8].  
Experimental 
Synthesis 
Au(PEt3)I was synthesized as described in Chapter 4 starting from commercially 
available Au(PEt3)Cl. A logP value of 4.6 was found for Au(PEt3)I making this complex by 
far the most lipophilic of the series. Indeed, logP values of 1.7 and 1.6 were, respectively 
measured for Au(PEt3)Cl and AF (see chapter 2 for details on the method for logP 
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determination). Single crystals of Au(PEt3)I, suitable for X-ray diffraction studies, were 
obtained by adding pentane to a concentrated solution of the compound in 
dichloromethane. The solution was kept at −20 °C for 1 week. After this time needle-
shaped crystals were formed (Figure 1).  
 
Fig.1: X-ray structure of complex Au(PEt3)I. The gold(I) ion is linearly coordinated to the 
I(1) and P(1) atoms, with distance of 2.5898(1) and 2.268(2) Å, respectively. The angle 
P(1)−Au(1)−I(1) is 178.89(6)°. 
The crystal structure was solved to 0.73 Å resolution. The geometry as well as the 
distances reported in Figure 1 are in good agreement with bond lengths and angles 
found in similar compounds retrieved from the CSD (v. 5.37 February 2016). It is worth 
reminding that the Au−I bond length generally increases as the hindrance of the 
substituents of the P atom decreases (P-tBu3, P-iPr3, P-Et3 of 2.56, 2.58, and 2.59 Å, 
respectively) [9].  
TrxR inhibition assay 
Thioredoxin reductase activity was determined by measuring the ability of the enzyme 
to directly reduce DTNB in the presence of NADPH. Rat liver TrxR (Sigma-Aldrich) was 
diluted with water to a concentration of 60 nM (2 U/mL). Aliquots of 25 μl of the 
enzyme solution were preincubated, for 5 min at 37°C, with 25 μl of 0.1 M K-phosphate 
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buffer pH 7.0, 5 mM EDTA and 0.25 mM NADPH, containing different concentrations of 
the gold complexes (from 1 μM to 1 nM). Afterwards, the reaction was started with 1 
mM DTNB and monitored spectrophotometrically at 412 nm, for about 10 min.  The 
noninterference of the compounds with assay components was confirmed by negative 
control experiments with enzyme-free solution. The IC50 values are the complex 
concentration decreasing the enzyme activity to 50%reported as means ± SD of three 
experiments, each carried out in duplicate. 
Melting tests 
The melting profiles of different DNA/drug mixtures were obtained by the absorbance 
data of the system (ShimadzuUV-2450 double-beam spectrophotometer) at different 
temperatures and 260 nm. The temperature is changed (ca. 3 °C increase each point) 
by means of the thermostatic bath connected to the spectrophotometer. Its exact value 
inside the cell department is measured through a digital thermometer.  The explored 
range was between 63 °C and 96 °C.  After each temperature change, the system is left 
to equilibrate for 30 min.   
Viscosimetric measurements  
Viscosity measurements were done using a Micro-Ubbelohde viscometer whose 
temperature is controlled by a thermostat (25 ± 0.1 ºC). Time of flow is measured by a 
digital stopwatch; the data used for each sample are the average of at least five 
repeated experiments (error within 5%). In all the measurements DNA concentration 
was kept constant at 2.5x10-5 M, whereas the drug concentration is varied in the 0 ≤ rb 
≤ 1.0 range. Each sample/mixture was left to equilibrate for 72h to ensure reaction 
completion. Particular case was devoted to the procedure of capillary cleaning and 
drying after each measurement. The sequence water –acetone – water – ethanol – N2 
flux is used. The DNA elongation is evaluated as the cubic root of the relative viscosity 
η/η° = (t-tsolv)/(tDNA-tsolv) where t, tsolv and tDNA are the efflux times in the capillary 
viscometer of the mixture, of the buffer (NaCl 0.1M, NaCacodylate 0.01M, pH 7) and of 
DNA alone respectively. Note that, under the described reaction condition, the efflux 
times are in the order of 8 minutes, so that small changes can be measured with high 
accuracy.  
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Assessments of Acute toxicity in vivo for Au(PEt3)I  
5-week-old, female athymic mice (Envigo) have been treated with Au(PEt3)I to assess 
acute toxicity of this potential anticancer Au-based drug. For this test was used the 
following protocol: intraperitoneal injections 2 time/week (3 weeks treatment) on 
three different groups (each of three mice). Each group was treated with a different 
dose of Au(PEt3)I (10, 15 and 30 mg/Kg). After the three weeks of treatment, mice were 
monitored for an additional week to find possible changes in their behaviour indicating 
stress or sufferance due to the drug administration. Sacrifice of mice was made at the 
end of the protocol through preliminary injection of anesthetic (Avertin).  The efficacy 
of the anesthetic was properly tested and verified.  Afterward, dissection of mice and 
collection of organs (i.e. liver, kidneys and spleen) was carried out. 
Results and Discussion 
Au(PEt3)I was investigated for its chemical and biological properties in solution in 
comparison to AF and Au(PEt3)Cl. The solution behaviour of the three species was 
mainly assessed by 31PNMR spectroscopy. The three compounds were solubilized in 
trizma base/CH3COOH, 6 mM, in the presence of 250 μL of H2O; 650 μL of CH3OH; 200 
μL of CD3OD, pH 7, and analysed at increasing time intervals. Notably, all three 
compounds manifest a high stability for several hours with no evidence of ligand 
detachment. Indeed, changes in the 31PNMR spectra could only be detected after very 
long incubation times. For Au(PEt3)I, no changes were seen after 72 h; however, after 
1 week of incubation, beside the signal falling at 41 ppm (assigned to the phosphorus 
in the neutral complex), a new signal of low intensity appeared at 47 ppm. This new 
signal is attributed to phosphorus in the cationic monocharged complex [Au(PEt3)2]+, 
which is likely formed through rearrangement, according to the equilibrium (Scheme 
1) [10, 11].  
 
Scheme 1: Ligand Scrambling Reaction of Au(PEt3)I. 
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The signal increases in intensity until day 14; no further changes in intensity were 
detected afterward, even after 35 days, indicating that the reaction has reached its 
equilibrium (Figure 2 for details).  
 
Fig.2: 31PNMR spectra (trizma base/CH3COOH 6 mM in a mixture of 250 μL of H2O; 650 
μL of CH3OH; 200 μL of CD3OD, pH 7) of Au(PEt3)I recorded at different time intervals. 
Formation of [Au(PEt3)2]+ was independently confirmed treating Au(PEt3)I with AgNO3, 
under the same solution conditions, and then analysing the reaction products by 
31PNMR and HR ESI-MS at different times intervals. When recording a 31PNMR spectrum 
immediately after treatment with AgNO3 we found only a signal falling at 30.43 ppm 
assignable to [Au(PEt3)(H2O)]+ species [12]. After five days, a new 31PNMR spectrum was 
recorded on the same sample: beside the signal at 30.43 ppm, a new one at 47.85 ppm 
was detected and assigned to the monopositive cation complex [Au(PEt3)2]+. Further 
confirmation came from ESI-MS analysis. In the spectrum recorded five days after 
treatment with AgNO3, we found three main signals at 315.1, 333.1, and 433.15 Da 
assignable, respectively, to the three species [Au(PEt3)]+, [Au(PEt3)(H2O)]+, and 
[Au(PEt3)2]+. Attributions were validated through theoretical simulation of the various 
species. Finally, to obtain an additional proof that the 31PNMR signal at 47 ppm 
corresponds to formation of [Au(PEt3)2]+ species, we synthesized this complex by 
treatment of Au(PEt3)Cl with an excess of triethylphosphine. The 31PNMR analysis of 
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the resulting product confirmed the obtainment of the desired compound and, 
accordingly, our assignment (see chapter 4 for further details on the synthesis and NMR 
spectrum). A quite different situation was found for the 31PNMR spectra of AF and 
Au(PEt3)Cl, for which no significant changes were detected even after 35 days of 
incubation. However, all three compounds show a large stability in solution even when 
incubated in the presence of NaCl 0.9% as well as in 10 mM PBS buffer, rendering them 
well suitable for pharmacological testing and application. Next, the antiproliferative 
properties of the three complexes were measured in vitro against HCT8, HCT116, HT29, 
and Caco2, four representative cell lines of colorectal cancer (CRC) as well as on HDF 
(human fibroblast, adult) and HEK293 (human embryonic kidney) cell lines. As 
displayed in Table 1, all three drugs produce potent cytotoxic effects on the selected 
CRC cell lines with IC50 values always falling in the 100−700 nM range. Au(PEt3)I is 
slightly less cytotoxic than the other two gold complexes.  
 
Complex HCT8 HCT116 HT29 Caco2 HDF HEK293 
AF 132 ± 16 180 ± 17 359 ± 35 465 ± 53 >5000 >5000 
Au(PEt3)Cl 105 ± 11 154 ± 22 122 ± 15 560 ± 93 >5000 >5000 
Au(PEt3)I 260 ± 28 290 ± 36 318 ± 90 706 ± 232 >5000 >5000 
 
Table 1: IC50 Values (nM) Determined for Au(PEt3)I, AF, and Au(PEt3)Cl (24 h 
Incubation).  
In any case, the presence of the thiosugar ligand is not an essential requirement for the 
cytotoxic action [13], in line with expectations. In addition, upon considering the close 
similarity in the measured IC50 values, substantial differences in the cellular uptake are 
unlikely. Remarkably, measuring the cytotoxic effects on two normal cell lines, HDF 
human fibroblast cells (adult) and HEK293 human embryonic kidney (Table 1), no 
cytotoxic effect was found for the three study complexes in the range 0−5000 nM. Next, 
in view of the fact that thioredoxin reductase (TrxR) is a likely important target for AF 
[14], we have comparatively quantified the inhibitory potency of the three drugs 
toward this enzyme. Results are summarized in Table 2.  
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Complex IC50 (nM) 
AF 105 ± 17.3 
Au(PEt3)Cl 51.3 ± 8.5 
Au(PEt3)I 193 ± 22.2 
Table 2: Thioredoxin Reductase Activity Assay. IC50 values (nM) were determined 
treating 2 U/L of TrxR with aliquots of AF, Au(PEt3)Cl, and Au(PEt3)I (from 1 μM to 1 
nM). Results are reported as average value for three independent experiments ± SD. 
It is interesting to note that the obtained IC50 values for TrxR inhibition are in line with 
those obtained for the cytotoxic effects on CRC cell lines (Table 1). This might imply that 
the observed cytotoxic effects are somehow related to the ability of these gold 
complexes to bind and inhibit TrxR. Moreover, results highlight and confirm that 
Au(PEt3)Cl is not only the most potent cytotoxic agent but also the most potent TrxR 
inhibitory agent of the series, though IC50 values for AF and Au(PEt3)I still fall in the 
nanomolar range. To better characterize the mechanistic aspects of the interactions 
occurring between these gold compounds and probable biological targets, we have 
studied their reactions toward the model protein lysozyme (HEWL) and the GG rich 
oligonucleotide CTACGGTTTCAC (ODN) through ESI-MS analysis. Notably, upon 
replacing the thiosugar ligand with a halide ligand, e.g., chloride or iodide, we observed 
a net change in metallodrug reactivity toward HEWL. Indeed, AF interacts appreciably 
with HEWL, apparently through formation of noncovalent adducts, where the neutral 
intact drug is bound to the protein (Figure 3); in contrast, both iodide and chloride 
derivatives do not react with HEWL even after long incubation times. 
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Fig.3: Close-up of deconvoluted ESI-MS spectrum (positive mode) of AF incubated 72 h 
(37 °C) with HEWL (10−4 M) in ammonium acetate buffer, 20 mM, pH 6.8; metal to 
protein ratio (3:1), 3% DMSO. 
This different behaviour might be ascribed to a crucial role of the thiosugar ligand in 
forming noncovalent protein adducts. Conversely, replacement of the thiosugar ligand 
with halide ligands greatly enhances reactivity toward oligonucleotide. In fact, both 
Au(PEt3)I and Au(PEt3)Cl coordinate this target through selective release of halide 
ligands roughly in the same manner (Figure 4); also, similar amounts of the 
corresponding adducts are formed.  
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Fig.4: Deconvoluted ESI-MS spectrum (negative mode) of Au(PEt3)I incubated 72 h (37 
°C) with ODN (10−4 M) in LC−H2O metal to protein ratio (3:1), 3% DMSO. 
In contrast, when performing the same experiment with AF, no adduct formation with 
ODN was observed; this finding is relevant even considering that AF does not react with 
double helix DNA as previously reported by Mirabelli and coworkers [15], and the same 
kind of reactivity is preserved toward the single strand ODN model. Notably, when AF 
is incubated with ODN, it only produces a main peak at 923 m/z assignable to the 
species in Figure 5, as previously reported [16].  
 
Fig.5: Structure of the main specie produced by AF: structure corresponds to the peak 
at 923 m/z. 
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Encouraged by the results obtained with ss ODN, the possible interactions of AF 
analogues with double-stranded DNA (more precisely, calf thymus DNA) were 
comparatively investigated by the ethidium bromide (EtBr) assay. DNA is first saturated 
with the EtBr probe producing a fluorescent intercalation complex (while free dye is 
non-emissive).  
Then, increasing amounts of the drug are added: a fluorescence decrease indicates 
progressive EtBr displacement and build-up of drug−DNA interactions [17, 18]. We 
found, indeed, that both Au(PEt3)Cl and Au(PEt3)I produce a net fluorescence decrease, 
while AF does not (Figure 5).  
  
Fig.6: DNA interaction investigated through EtBr displacement.  
The emission decrease is limited, in agreement with the non-intercalative nature of the 
binding, yet significant. Melting temperatures (the temperature of the inflection point 
of the sigmoid melting profile) of drug−DNA mixtures do not vary appreciably from 
Auranofin 
Au(PEt3)Cl 
Au(PEt3)I 
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those of DNA alone (changes in the melting temperatures are in the range ±2 °C in 
agreement with monodentate coordination of the drug to DNA strands; Fig.7).  
 
Fig.7: Melting profiles of DNA/AF (triangles), DNA/Au(PEt3)Cl (diamonds) and 
DNA/Au(PEt3)I (circles). [C] DNA = 2.5x10-5 M, rb = 1.0 in all cases, NaCl 0.1M + 
NaCacodylate 2.5 mM buffer, pH 7). Melting temperatures were respectively 81.5 °C, 
82.1 °C and 81.1 °C.; percentage of absorbance change at 260 nm reported in the plot 
is calculated as % A change = 100 × (A – A0)/(A∞ – A0) where A is the value read at any 
temperature, whereas A0 and A∞ are the values of the two, respectively initial and final, 
plateaus as calculated by the sigmoidal fit). The melting temperature of DNA alone was 
measured and found to be 82.3 °C. 
This result is in agreement with the covalent binding of the Au(I) metal ion to one 
filament as this binding feature is not supposed to significantly alter the energy needed 
for strands separation. Conversely, viscosity undergoes significant changes for 
 78 
 
Au(PEt3)Cl/DNA and Au(PEt3)I/DNA systems compared to the control (Figure 8), 
suggesting that the bound drugs significantly affect the helix flexibility. This strong 
effect, which is not observed upon AF addition, confirms that the Auranofin analogues 
manifest a reactivity significantly different from AF and are able to bind ds-DNA.  
 
Fig.8: Viscometric plots (25 °C) for Au(PEt3)I/DNA (open circles), Au(PEt3)Cl/DNA 
(diamonds), and AF/DNA (squares) systems. rb = [drug]/[DNA] (base pairs), [DNA] = 2.5 
× 10−5 M, η/η° = (t −tsolv)/(tDNA − tsolv) where t, tsolv, and tDNA are the efflux times in the 
capillary viscometer of the mixture, of the buffer (NaCl 0.1 M, Na−cacodylate 0.01 M, 
pH 7) and of DNA alone, respectively. 
Finally, in vivo acute toxicity experiments for Au(PEt3)I were carried out to assess 
whether this complex is tolerated in murine model. Three doses were tested (i.e., 10, 
15, and 30 mg/kg) on three groups of animals (each group consisted in three mice). The 
weight and the behaviour of mice was monitored every day during all the treatment, 
and there was no evidence for weight loss; also, no evidence for loss of appetite and 
mobility reduction were found. Remarkably, neither microscopic or macroscopic 
alteration was found in liver, kidneys, and spleen. Obtained results highlight that the 
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treatment has been well tolerated in murine models and that the toxicity profile of this 
drug is low and similar to that reported for AF [19].  
Conclusions 
Similarly to AF and Au(PEt3)Cl, Au(PEt3)I shows a high stability under physiological-like 
conditions while manifesting a far greater lipophilic character. Interestingly, Au(PEt3)I 
retains the large cytotoxic effects of AF and Au(PEt3)Cl toward four representative CRC 
cell lines, with the measured IC50 values still falling in the nanomolar range and no 
cytotoxic effect on human fibroblast cell line and human embryonic kidney cells. This 
implies that the presence of the thiosugar moiety is not mandatory for the 
pharmacological action. The TrxR assay reveals that both Au(PEt3)Cl and Au(PEt3)I retain 
the potent inhibitory action of AF (nanomolar range), being consistent with their 
observed cytotoxic effect, with AF and Au(PEt3)Cl slightly more active than Au(PEt3)I. 
However, mechanistic differences were highlighted among the three investigated gold 
complexes with both Au(PEt3)I and Au(PEt3)Cl being unreactive toward HEWL but 
capable of binding to a standard ss-ODN sequence and to ds-DNA. At variance, AF can 
bind noncovalently to the model protein but does not form coordinative adducts to 
ssODN and does not bind calf thymus DNA. In our opinion, the present results are of 
particular interest for the following reasons: 
1. Substitution of the thiosugar with iodide and chloride “tunes” the reactivity of these 
compounds for model biological targets rendering them more selective toward oligo 
and polynucleotides. At variance from AF, where the tetraacetate-thiosugar moiety 
allows formation of noncovalent adducts with lysozyme, this kind of binding is not 
observed in the cases of Au(PEt3)I and Au(PEt3)Cl. Yet, it is worth reminding that even 
AF is not able to form coordinative bonds to HEWL. Binding of gold(I) metal center to 
histidine and methionine residues of lysozyme was previously described mainly as a 
naked cation [20]; but this does not occur for AF and its analogues due to the very high 
stability of the ligands and their steric hindrance. Furthermore, these differences in 
reactivity toward the model protein HEWL do not correlate with their strong inhibitory 
power toward TrxR, being this latter aspect most probably related with the very high 
affinity of gold for the selenium donor and thus for the selenocysteine residue.  
2. The enhanced reactivity of the gold(I) center toward the model oligonucleotide and 
the double helix DNA upon replacement of the thiosugar ligand with halide ligands may 
be the result of the greater lability of the gold−halide bond compared to the gold−sulfur 
bond [13]; the guanine residue of nucleic acids that is highly accessible may “assist” 
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halide detachment. Yet, this augmented reactivity for DNA molecules does not lead to 
enhanced cytotoxic effects. This might support the view that AF and also its halido 
analogues exert their strong cytotoxic effects mainly through DNA-independent 
mechanisms [21]. 
3. The in vivo acute toxicity test carried out in a murine model, for the treatment with 
the complex Au(PEt3)I, does not show any side effects, and the treatment has been well 
tolerated. This evidence is of great significance and warrants further preclinical 
assessments. 
Overall, these findings are of significant interest if one considers that even small 
differences in biomolecular reactivity may result in large differences in the respective 
pharmacodynamic and pharmacokinetic profiles. In addition, the far greater lipophilic 
character of Au(PEt3)I might lead to an enhanced bioavailability of the latter drug. 
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6. Au(PEt3)I complex: in vivo studies for the treatment of 
ovarian cancer 
Introduction 
Encouraged by the results set out in chapter 5, we decided to extend the studies upon 
in vivo models. Moreover, Auranofin (AF) is generally reputed as a reasonably safe drug 
for human use, even for long chronic treatments [1,2]. On the ground of its antiparasitic 
and anticancer properties [3-10], AF in the course of the last years has entered many 
distinct clinical trials, two of them (ovarian and lung cancer) still ongoing and one 
(leukemia) closed [11−13]. Results of these trials have not been disclosed yet. At the 
same time, considerable evidence has been gathered that a few specific biomolecular 
targets such as the enzyme thioredoxin reductase, the proteasome system, the NF-κB 
pathway and other transcription factors, are crucially involved in mediating the cellular 
effects of AF as well of other gold (I/III) compounds [14−18]. It has been hypothesized, 
and then demonstrated, that the biological and pharmacological properties of AF might 
be kept and hopefully improved/modulated by replacing the thiosugar ligand with 
other ligands such as various halides. In principle, replacement of the thiosugar ligand 
with halide ligands may lead to an increased lipophilicity and an enhanced drug 
bioavailability and biodistribution. However, this modification should not affect 
substantially the drug’s pharmacological profile, as the invariant [Au(PEt3)]+ moiety is 
assumed to be the “true pharmacophore” whereas the thiosugar ligand is believed to 
act mainly as a carrier ligand [18]. Accordingly, the actions of 
iodido(triethylphosphine)gold(I) complex, Au(PEt3)I (AFI), and AF, have been 
comparatively analysed toward ovarian cancer models both in vitro and in vivo. AFI is 
obtained by replacement of the thiosugar ligand with an iodide ligand according to the 
reported synthetic procedures [18] (see chapter 4 for detailed synthesis and 
characterization). The chemical structures of AF and AFI are shown in Figure 1. 
 
Fig.1: Chemical structures of Auranofin and AFI. 
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Experimental 
Chemical 
Auranofin has been purchased from Vinci Biochem srl. AFI was synthesized and 
characterised as described in Chapter 5. 
Assessment of cell death by flow cytometry  
Cell death was analysed by TACS Annexin V/PI Kit (Trevigen) according to the 
manufacturer’s instructions. Briefly, control, AF, and AFI A2780-treated treated cells 
for 72 h with 72 h-exposure IC50, were trypsinized,  washed  with  PBS  and  
resuspended  in  staining  solution  for  15  min  in  the  dark.  Cells were analysed by 
FACSCanto flow cytometer (BD Biosciences). Gated cells were plotted on a dot-plot 
showing Annexin-V staining and propidium iodide (PI) staining. Percentage of   
apoptotic/necrotic cells was determinate adding Annexin V positive (early apoptotic)  
cells to Annexin/PI positive ones (late apoptotic) and to PI positive cells (necrotic cells). 
Assessment of caspase activity by flow cytometry  
For Caspase-3 activity determination control, Auranofinand Et3PAuI A2780-treated 
cells for 72 h with 72 h-exposure  IC50,  were  trypsinized,  washed  with  PBS  and  
resuspended  in  FAM-FLICATM  Caspases  solution (Caspase  FLICA  kit  FAM-DEVD-
FMK,  ImmunoChemistry  Technologies)  for  1  h  at  37°C,  following  the manufacturer’s  
instruction.  Cells were washed with PBS and analysed by FACSCanto flow cytometer 
(BD Biosciences). 
Cell growth inhibition studies (Sulforhodamine B assay) 
The cytotoxic effects of the complexes were evaluated on the growth of A2780. Both 
compounds were initially diluted in DMSO as stock solutions (20 mM), further dilutions 
have been performed in PBS (0.5% DMSO present at the higher tested concentration). 
Exponentially growing cells were seeded in 96-well microplates at a density of 5*103 
cell/well. After cell inoculation, the microtiter plates were incubated under standard 
culture conditions (37°C, 5% CO2, 95% air and 100% relative humidity) for 24 h prior to 
the addition of study compounds. After 24 h, the medium was removed and replaced 
with fresh medium containing drug concentrations ranging from 0.003 to 100 μM for a 
continuous exposure of 24 and 72 h for both study compounds. For comparison 
purposes the cytotoxicity effects of cisplatin measured in the same experimental 
conditions were also determined. According to the procedure the assay was  
terminated by the addition of cold trichloroacetic acid (TCA). Cells were fixed in situ by 
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10% TCA and stained by sulforhodamine B (SRB) solution at 0.4% (w/v) in 1% acetic 
acid.  After staining, unbound dye was removed by washing five times with 1% acetic 
acid and the plates were air dried. Bound stain was subsequently solubilized with 10 
mM tris base, and the absorbance was read on an automated plate reader at a 
wavelength of 540 nm. The IC50 drug concentration resulting in a 50% reduction in the 
net protein content (as measured by SRB staining) in drug treated cells as compared to 
untreated control cells was determined after 72 h of drug exposure.  
Tolerability studies  
Nude mice were randomly grouped according to their body weight with four mice per 
test substance, which was administered intraperitoneally using two different doses (20 
mg/kg and 40 mg/kg).  The complexes have been solubilized in DMSO and then diluted 
in bidistillated water with 5% DMSO present in the final solution. Only one 
administration was performed, followed by a three weeks observation period; in this 
time, we monitored daily possible signs of toxicity including weight loss, mobility 
reduction, dehydration, hunched posture, ruffled fur, and loss of appetite or lethargy.  
Animals were euthanized if their body weight loss exceeded 15% within the first 24 h 
after treatment or 20% at any other point in the study. 
Biodistribution studies 
For the assessment of biodistribution of AF, AFI and, nude mice (female 5 weeks old) 
were randomly grouped according to their body weight with three mice per test 
substance, which was administered with intraperitoneal injection using a single dose 
(10 mg/kg).  Mice from each group were anesthetized, bled, and sacrificed, and organs 
dissected (spleen, liver, kidney, heart) at 24 hours.  After blood collection, tissues were 
weighed and solubilized, and the amount of gold in each tissue was determined   
through   ICP-AES   analysis   after   mineralisation   with   HNO3.   The   determination   
of   gold concentration in the blood or in the organs was performed by a Varian 720-ES 
Inductively Coupled Plasma Atomic Emission Spectrometer (ICP-AES) equipped with a 
CETAC U5000 AT+ ultrasonic nebulizer, in order to increase the method sensitivity. 
Before the analysis, samples were weighed in PE vials and digested in a thermo-reactor 
at 80 °C for 24 h with 2 mL of HNO3 (35 % suprapure grade) 0.5 mL of H2O2 suprapure 
grade.  After digestion, the samples were diluted to 6 mL with ultrapure water (≤18 
MΩ).  5.0 mL of each sample were spiked with 1 ppm of Ge used as an internal standard 
and analysed.  Calibration standards were prepared by gravimetric serial dilution from 
a commercial standard solution of Au at 1000 mg L−1. The wavelength used for Au 
determination was 267.594 nm whereas for Ge the line at 209.426 nm was used. The 
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operating conditions were optimized to obtain maximum signal intensity, and between 
each sample, a rinse solution of HNO3 (35 % suprapure grade) was used in order to 
avoid any “memory effect”. 
Results and discussion 
Replacement of the thiosugar ligand with iodide results into a greatly increased 
lipophilic character (a logP value of 4.6 has been measured by ICP-AES in the chapter 5) 
with respect to both Au(PEt3)Cl and AF (this latter compound has been previously 
described and used experimentally for rheumatoid arthritis treatment) [19] for which 
logP values of 1.7 and 1.6 were measured, respectively [18]. In spite of that, AFI is still 
appreciably soluble in aqueous solutions, where it manifests a very high stability as 
documented by a previous systematic NMR analysis, carried out in different 
environments including biological media [18,20]. As reported in Figure 2, 31PNMR 
results clearly demonstrate a high stability of AFI, with no changes in the structure of 
the molecule, even in the presence of a large excess of sodium chloride (up to 100 mM).  
 
  
Fig.2: 31PNMR spectrum recorded after incubation (24h) of AFI in 250 L MeOD + 250 
L NaCl 100mM. The signal detected at 41.56 ppm is in agreement with previous 
characterizations (see chapter 4). 
The documented stability in physiological-like conditions makes the compound an ideal 
candidate for biological testing. The antiproliferative properties of AFI compared to AF 
have been investigated in vitro toward A2780 human ovarian cancer cells. As displayed 
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in Table 1, both compounds produce potent cytotoxic effects with IC50 values falling in 
the high nanomolar range.  
 
Table 1: Inhibitory effects of AF, AFI, and Cisplatin on A2780 cells following 72 h drug 
exposure as determined by the Sulforhodamine B assay. 
AFI is slightly more cytotoxic than AF and both result more effective than cisplatin, the 
well-known anticancer metal compound. These results are consistent with those 
previously obtained in colon cancer cell lines for the same gold compounds and recently 
published literature [18] further supporting the concept that the presence of the 
thiosugar ligand is not an essential requirement for the cytotoxic action and that 
substantial differences in the cellular uptake, despite the difference in the logP value, 
between AFI and AF are unlikely to occur. Remarkably, in agreement with a previous 
observation [18] no appreciable cytotoxic effects were detected for AFI in normal cell 
lines, i.e., human fibroblasts (HDF cell line) and human embryonic kidney cells (HEK293) 
over the concentration range 0−5000 nM. Then, we examined whether AFI and AF are 
able to induce apoptosis in A2780 cells; accordingly, we performed flow cytometry 
analysis of annexin V/propidium iodide-stained A2780 cells, treated with these two 
gold compounds, at the respective IC50 values, for 72 h. As shown in Figure 3A, the 
percentage of apoptotic cells in AF- and AFI-treated samples is significantly increased 
(control vs AF, p = 0.0121; control vs AFI, p = 0.0107).  
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In order to evaluate and quantitate apoptosis via caspase activity, we checked the 
activity of caspase 3 by FAM-FLICA Caspase-3 Assay Kit (Fig.3B). Four independent 
experiments were performed for both assays reported in Fig.3A and Fig.3B. The 
statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s 
multiple comparisons test using Graphpad Prism v 6.0 (*p<0.05, **p<0.01). The 
induction of apoptosis observed for AF and its iodide analogue may be related with the 
strong thioredoxin reductase inhibition potency. Indeed, the IC50 values for the 
inhibition of the enzyme are generally in nice agreement with cytotoxicity values [18]. 
The results collected evidenced that both gold compounds induce apoptosis through a 
caspase 3 activation, with AF being slightly more effective than AFI (control vs AF, p = 
0.0037; control vs AFI, p = 0.04). AFI was subsequently evaluated in vivo in comparison 
to AF in two different ovarian cancer models, i.e., a xenograft subcutaneous and an 
orthotopic model. Preliminarily, drug tolerability studies were carried out to assess the 
in vivo safety of AFI. The single-dose tolerability was evaluated in athymic nude mice 
over a 3-week observation period. AFI was administered by intraperitoneal (ip) 
injection using two different doses (20 and 40 mg/kg). Only a single administration was 
performed, followed by a 3-week observation period; animals were controlled daily, 
and no signs of sufferings such as weight loss, mobility reduction and appetite 
reduction were registered. In addition, a pilot singlicate study for gold biodistribution 
has been carried out and a generalized higher accumulation for AFI, both in organs and 
in the peripheral blood, was highlighted (Figure 4).  
 
Fig.4A: Biodistribution plots for Auranofin and AFI. 
 90 
 
 
 
Fig.4B: Biodistribution plots for Auranofin and AFI. 
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Fig.4C: Biodistribution plots for Auranofin and AFI. 
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Based on the above observations, we can hypothesize that the detected differences in 
the in vivo activity of the two compounds could be due to their different lipophilic 
character leading to an enhanced bioavailability and more favourable 
pharmacokinetics for AFI. The xenograft model consisted of 1x106 A2780 cells 
implanted subcutaneously (sc) in both flanks of the animals. The growth of the tumor 
masses was measured daily with caliper and the treatment started when the volume 
of the masses reached 60 mm3. The treatment was performed by intraperitoneal 
injections (three times a week for 2 weeks of treatment) of AF and AFI, both 15 mg/kg. 
The growth of the tumor masses was monitored over 21 days and time course is shown 
in Figure 5A and 5B respectively.  
 
Fig.5: In vivo anticancer activity evaluation of gold compounds in a xenograft 
subcutaneous (sc) model of ovarian cancer cell line.  (A, B) Time course of tumor growth 
in control, AF, and AFI treated mice (4 animals per group), injected with A2780 cells sc.  
Treatments started when the volume of the masses reached 60 mm3 (after 7 days from 
cells injection); the administration   was performed   by intraperitoneal injections (three 
times a week for two weeks of treatment) of AF and AFI compounds (15 mg/kg). Data 
are reported as the mean ± SD. 
At the end of the experiments, mice were sacrificed and the explanted masses 
measured; the volume (cm3) was calculated using the ellipsoid equation [21]. 
Remarkably, treatment with both AFI and AF was accompanied by a strong decrease of 
the tumor volume determined at the sacrifice (Figure 6, control: 2.96 ± 0.06 vs AFI: 0.56 
± 0.20, p < 0.01; control: 2.96 ± 0.06 vs AF: 0,79 ± 0,27, p < 0.01).  
 93 
 
 
Fig.6: In vivo anticancer activity evaluation of gold compounds in a xenograft 
subcutaneous (sc) model of ovarian cancer. Mean volume of tumor masses obtained at 
the sacrifice, after 3 weeks from injection of A2780 cells. Data are reported as the mean 
± SD (*p < 0.05, **p < 0.01). 
The above experimental protocol did not alter the behaviour, vitality, or weight of 
treated mice. Subsequently, the in vivo anticancer activity of AFI versus AF was 
assessed in an orthotopic model of ovarian cancer, a model that better represents the 
cancer behaviour and response to therapy. Thirty female athymic nude mice were 
injected in the ovarian bursa (5x105 cells each mouse) with A2780 cells transfected with 
the firefly luciferase gene (A2780-luc). Autopsy confirmed that ovarian cancer occurred 
in all animals and representative images of the procedure and of tumor masses are 
reported in Figure 7A. The animals were divided in three groups of treatment (10 mice 
each): controls, AF treated and AFI treated. The administration schedule was the 
following: mice received compounds (15 mg/kg) ip three times a week for 2 weeks. The 
rationale for such a treatment schedule relied on the schedule reported by Mirabelli et 
al [5] and on the above-reported biodistribution data (Fig.4) showing that 
administration of 15 mg/kg gives rise to a peak peripheral blood concentration of 
823.19 and 944.17 ng/mL, for AF and AFI, respectively, after 24 h. Mice were monitored 
daily, and the luciferase activity signal was quantified weekly (representative panels are 
reported in Figure 7B). Both gold compounds effectively reduced the tumor burden 
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(Figure 7B); notably, AFI is already very effective in antitumor activity after few doses 
(i.e., 1 week of treatment) leading to an almost complete tumor remission, as 
evidenced by the drastic reduction of the bioluminescent signal (ROI levels) compared 
to the control group (control: 20260 ± 4631 vs AFI: 4729 ± 2881; p < 0,01) (see graph in 
Figure 7C). The tumor masses of the sacrificed animals after 3 weeks of treatment were 
collected and measured with caliper; the volume (cm3) was calculated using the 
ellipsoid equation even for this model [21]. Most important, the tumor masses of the 
animals treated with AFI showed a very strong reduction of the volume compared both 
to the control group (control vs AFI p < 0.05) and to the AF group (AF: 6.86 ± 1.57 vs 
AFI: 1.00 ± 0.70, p < 0.01) (Figure 7D). This latter evidence points out that AFI is a more 
effective anticancer drug compared with AF in our animal model. 
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Fig.7: (A) Orthotopic model establishment: injection of 1x106 A2780-luc cells in the 
ovary bursa of nude mice. Representative macroscopic images of ovarian tumor masses 
obtained are showed in the bottom panels. (B) Representative pseudocolor BLI images 
tracking A2780-luc cells emission in mice, 7, 14, and 21 days after A2780-luc injection. 
Color bar represents light intensity levels reported as counts per minute (cpm). (C) 
Levels of ROI after 1 week of treatment; data are reported as mean of each group (n = 
10 animals/group) ± SD (**p < 0.01). (D) Volume of tumor masses (mean ± SD) at the 
sacrifice after 3 weeks from injection of A2780-luc cells (control group, n = 8; AF, n = 5; 
AFI, n = 5). *p < 0.05, **p < 0.01. 
Conclusions 
In conclusion, we have shown here that a specific structural modification of the 
repurposed gold(I) drug AF, now under consideration in clinical trials for cancer 
treatment, i.e., the substitution of the thiosugar ligand with iodide, affords a distinct 
gold(I) complex AFI, whose anticancer profile in vitro roughly resembles that of AF. This 
confirms that, even in the present ovarian cancer model, the thiosugar ligand is not 
mechanistically indispensable and that the [Au(PEt3)]+ moiety is likely to be the true 
pharmacophore. Very interestingly, in our in vivo models, AFI, has turned out to be far 
more effective than AF in contrasting tumor growth. Particularly impressive are the 
results and the differences between AF and AFI observed in the orthotopic model of 
ovarian cancer. AFI is found to induce a very large tumor regression after only 1 week 
of treatment, as pointed out by the decrease of the bioluminescent signal. A 
conspicuous shrinkage of the tumor is still evident after 3 weeks. The enhanced 
anticancer activity observed in this orthotopic model might well arise from the far 
greater lipophilicity of AFI, which might lead to a more favorable pharmacokinetics and 
biodistribution. Notably, the improved in vivo anticancer activity of AFI over AF does 
not bring about any increased systemic toxicity, making AFI a promising new drug 
candidate. In view of its far superior efficacy in animal models, AFI merits a more 
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extensive preclinical testing as it might be a valuable alternative to AF in cancer clinical 
trials. 
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7. Silver(I) carbenes as a new class of chemotherapeutic 
agents 
Introduction 
Since cisplatin was first approved by the US Food and Drug Administration (FDA) for 
cancer treatment in 1978, the development of new and more effective metal-based 
anticancer drugs has been a primary challenge for scientists [1]. Despite great efforts 
made in the past few decades, only two other platinum-based drugs (i.e., carboplatin 
and oxaliplatin) and one arsenic-based drug (i.e., As2O3, trisenox) [2] have received 
approval worldwide as anticancer agents. In addition, even considering the important 
improvements in the administration protocols, some of the major problems associated 
to the use of Pt drugs still remain unsolved [3]. A family of metal-based compounds 
with promising features is that of carbene complexes. Metal–N-heterocyclic carbene 
(NHC) complexes have been extensively investigated in recent years for various 
applications, including medical and pharmacological ones. Particularly attractive for 
biomedical purposes is the high stability of these complexes, which is often greater 
than for the corresponding metal complexes with phosphane ligands [4]. This is 
one of the reasons why the synthesis and characterization of the carbene complexes of 
several transition metals has gained so much attention. Many gold, copper, platinum, 
palladium, iridium, ruthenium, and silver carbenes have now been tested as 
experimental drugs with promising results [5]. Beyond the above motivations, the 
interest in anticancer applications of carbene complexes is also driven by the 
observation that gold or silver carbene compounds seem to have non genomic targets 
for their pharmacological activity. In this frame, many research groups worldwide have 
reported the capacity of gold-based carbenes to bind thioredoxin reductase (TrxR), an 
important enzyme involved in cellular redox homeostasis; apparently metal binding 
occurs at the level of the redox-active C-terminal motif bearing a selenocysteine 
residue [6]. In 2013, Rigobello and co-workers published a paper on the synthesis, 
characterization, and anticancer properties of two novel silver- or gold-based carbene 
complexes bearing a 1-(anthracen-9-ylmethyl)-3-methylimidazol-2-ylidene ligand with 
fluorescence properties. These compounds showed pronounced in vitro anticancer 
properties and were also found to be strong inhibitors of TrxR. Remarkably, the silver 
complex was more efficient than its gold counterpart in contrasting cancer cell 
proliferation as well as in inhibiting TrxR activity [7]. We were interested to evaluate 
whether small structural modifications of the 1-(anthracen-9-ylmethyl)-3-
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methylimidazol-2-ylidene silver chloride complex ([Ag(MIA)]Cl), such as replacement of 
the imidazole methyl substituent with an ethyl group, might appreciably affect the 
chemical and biological profiles of the resulting compound. We soon realized that upon 
ligand modification, when the product is slowly crystallized from the reaction mixture, 
the structure of the silver center turned out to be different. Indeed, at variance with 
the parent complex bearing the methyl substituent at the imidazole 3-position, a 
structure of the type [Ag(NHC)2]X was the only one afforded both in the solid state and 
in solution. Thus, we report herein the synthesis and chemical and biological features 
of this fluorescent complex characterized by the ability to inhibit TrxR apparently 
through direct binding to the active site redox motif. Remarkably, this latter process 
has been conveniently investigated by high-resolution ESI-MS using the C-terminal 
dodecapeptide of thioredoxin reductase hTrxR (488–499) bearing the active site redox 
motif, with a method already established in our laboratory [6a, b].  
Results and Discussion 
Synthesis and characterization of [Ag(EIA)2]Cl  
We first prepared the studied complex according to the synthetic procedure reported 
in the Experimental Section below. The complex was designed by modifying the ligand 
reported by Rigobello and co-workers in their work (see Figure 1). After synthesis of 
the modified ligand, we intended to prepare its 1:1 silver complex, i.e., Ag(EIA)Cl. In 
contrast to expectations, through slow crystallization of the product, as described in 
the Experimental Section, we obtained selectively and in good yield a product which 
turned out to correspond to the bifunctional silver complex [Ag(EIA)2]Cl.  
 
Fig.1: Structures of the ligand previously reported (left) [7] and of the modified ligand 
5 used in this work (right, see Scheme 1). 
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Crystal structure 
The crystal structures of the free ligand i.e. 1-(anthracen-9-ylmethyl)-3-ethyl-1H-
imidazol-3-ium chloride (5) and of [Ag(EIA)2]Cl show that the ligand in both molecules 
retains the same conformation with respect to the mean planes containing the 
anthracene ring and the ethylimidazole moiety (88.55 in (5) compared with 82.25 in 
[Ag(EIA)2]Cl). In contrast, the torsion angle of the ethyl pendant varies from -44.15° in 
(5) to 77.17° in [Ag(EIA)2]Cl. The solid-state crystal structure of [Ag(EIA)2]Cl confirms the 
bifunctional structure already described in solution (Figure 2). Further  crystallographic 
data are reported in Experimental Section (Table 4). 
 
Fig.2: X-ray structure of complex [Ag(EIA)2]Cl: C-Ag bond length: 2.093(4) Å; C-Ag-C’ 
angle: 167.7° (C’ is reported by the symmetry operation -x+1,+y,-z-1/2). 
These results point out that, at variance with [Ag(MIA)]Cl, the small modification made 
at the imidazole 3-position strongly affects the nature of the resulting species, leading 
to a final product characterized by two carbene ligands bound to the metal center both 
in the solid state and in solution. 
UV/Vis absorption and emission spectra 
To test the complex stability with respect to dissociation in solution, we recorded 
UV/Vis absorption spectra of [Ag(EIA)2]Cl in buffered aqueous solutions at physiological 
pH. [Ag(EIA)2]Cl displays the typical structured absorption band of the anthracene 
chromophore, with a maximum at 370 nm (see Figure 3 below). This band does not 
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show any change within 24 hours, testifying the complex stability in aqueous medium 
(Figure 3).  
 
Fig.3: Time course spectra of [Ag(EIA)2]Cl (10-5M, phosphate buffer 50 mM pH 7.4, 1% 
DMSO) for 24 h 
In Figure 4 the emission spectra of [Ag(EIA)2]Cl and of free ligand are reported at 
different excitation wavelengths. At 350 nm of excitation wavelength the spectrum of 
[Ag(EIA)2]Cl shows three main emission bands falling at 395, 420, and 440 nm. 
Interestingly, the presence of the silver atom does not significantly affect the 
spectrophotometric properties of the ligand; these are substantially unaltered and 
almost superimposable to those of the free ligand. 
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Fig.4: Emission spectra of ligand (A) and [Ag(EIA)2]Cl (B) (10-8 M in 50 mM phosphate 
buffer pH 7.4 in presence of 0.001 % DMSO): black line λexc=335 nm, blu line λexc=350 
nm, orange line λexc=368 nm, pink line λexc=388 nm and red line λexc=405 nm.  
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 Cytotoxic effects and cellular uptake 
Next, the in vitro cytotoxic effects of [Ag(EIA)2]Cl toward human SH-SY5Y 
neuroblastoma cells were measured in comparison with cisplatin (the clinically 
established drug in the treatment of neuroblastoma) and [Ag(MIA)]Cl. The results 
highlighted that [Ag(EIA)2]Cl possesses cytotoxic properties greater than both 
compounds. In particular, an IC50 value of 1.059 +/- 0.042 M was determined, which 
is about 10- and 2-fold lower than cisplatin and [Ag(MIA)]Cl, respectively (Table 1).  
 
 
Table 1: IC50 values in SH-SY5Y cells determined for [Ag(EIA)2]Cl, cisplatin, and 
[Ag(MIA)]Cl. 
Uptake experiments were subsequently performed to assess whether the different 
logP values of these compounds (which may be tentatively associated with different 
capacities to permeate the cell membrane) significantly affect cellular accumulation. 
Indeed, the three compounds show rather different logP values: -2.4 for cisplatin [8] 
and 0.90 and 0.50 for [Ag(EIA)2]Cl and [Ag(MIA)]Cl, respectively. Results of the uptake 
experiments are reported in Table 2.  
 
Table 2: Metals level measured after 30 min exposure of SH-SY5Y cells to [Ag(EIA)2]Cl, 
cisplatin, and [Ag(MIA)]Cl at 10 mm. 
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It is observed that [Ag(EIA)2]Cl shows a far higher ability to enter cells, with its uptake 
being about 10-fold greater than cisplatin and about 6-fold greater than [Ag(MIA)]Cl. 
The increased cell internalization of [Ag(EIA)2]Cl is probably correlated with its higher 
lipophilicity. In turn, the greater cell internalization might explain its higher cytotoxicity.  
TrxR inhibition by [Ag(EIA)2]Cl  
Because the cellular redox system and, more specifically, TrxR are the likely targets for 
the cytotoxic effects of gold and silver carbene complexes [6, 7, 9], we decided to 
determine the inhibitory potency of [Ag(EIA)2]Cl toward this enzyme (Table 3).  
 
 
Table 3: Thioredoxin reductase activity assay. 
The experiments were done according to the procedure detailed in the Experimental 
Section [10]. The obtained IC50 value, falling in the sub-micromolar range, indicates that 
[Ag(EIA)2]Cl strongly inhibits TrxR, with its inhibitory potency in good agreement with 
its cytotoxic effects toward the SH-SY5Y cancer cell line.  
MS studies of the interaction between [Ag(EIA)2]Cl and the C-terminal dodecapeptide of 
hTrxR.  
To determine the molecular basis of TrxR inhibition, [Ag(EIA)2]Cl was incubated with 
the C-terminal dodecapeptide of hTrxR typically used as a model for the interaction of 
metal compounds with this enzyme (Figure 5) [6]. Indeed, this latter dodecapeptide, 
with the sequence Ac-SGGDILQSGCUG-NH2, corresponds to the tryptic C-terminal 
fragment (488–499) of hTrxR. 
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Fig.5: ESI-MS spectrum of the C-terminal dodecapeptide hTrxR (Ac-SGGDILQSGCUG-
NH2) dissolved in MilliQ water (10-4M). The inset shows the characteristic selenium 
isotopic pattern. 
 
In the peptide sequence, the N-terminal residue is acetylated and the C-terminus is 
amidated to avoid undesired interactions with the metal compound. The mass 
spectrum of this peptide is displayed in Figure 5, showing an intense peak at m/z 
1183.39 Da. The inset shows greater detail of the characteristic isotopic pattern due to 
the presence of a selenocysteine residue. The ESI-MS spectrum recorded for 
[Ag(EIA)2]Cl in the presence of the dodecapeptide bearing the redox-active motif of 
TrxR, revealed that the metal compound reacts rapidly with this peptide. Indeed, after 
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2 h of incubation at 37 °C, the mass spectrum (Figure 6) clearly shows the presence of 
two main signals: one at m/z 1469.54 Da (corresponding to the monoadduct), and one 
at m/z 1755.69 Da (belonging to the bisadduct) in which one or two carbene ligands, 
deprived of the metal center, are bound to the peptide.  
 
Fig.6: ESI-MS spectrum of the C-terminal dodecapeptide hTrxR (Ac-SGGDILQSGCUG-
NH2) dissolved in MilliQ water (10-4M) in the presence of 5.0 equiv dithiothreitol (DTT) 
and 1.0 equiv [Ag(EIA)2]Cl incubated for 2 h at 37 °C. The inset shows the isotopic 
pattern for the bis-adduct. 
 108 
 
Assignments were consistent with theoretical simulations of the isotopic pattern, 
which are in very good agreement with the experimental data depicted in the insets of 
Figure 6. The peak at m/z 1205.37 Da is assigned to the unreacted peptide associated 
with sodium. To confirm this unconventional reactivity, we carried out the same ESI-
MS experiments using the complex bis(1-(anthracen-9-ylmethyl)-3-propylimidazol-2-
ylidene) silver bromide ([Ag(PIA)2]Br), that is, the same complex with a propyl 
substituent at imidazole position 3. This complex was synthesized by following the 
same synthetic route as in the case of [Ag(EIA)2]Cl and characterized accordingly. Its 
crystal structure was also determined (Experimental Section, Table 4). A reactivity 
superimposable to that of [Ag(EIA)2]Cl emerged, indicating that the uncommon 
mechanism of binding described in the case of [Ag(EIA)2]Cl is conserved upon 
replacement of the ethyl substituent at imidazole position 3 with a propyl group. 
Additionally, the same incubation was carried out with [Ag(MIA)]Cl: the 
monofunctional silver complex reported by Rigobello and colleagues [7]. At variance 
with the two bifunctional silver complexes, i.e., [Ag(EIA)2]Cl and [Ag(PIA)2]Br, no 
adducts were found. Next, to gain further insight into the mechanistic aspects involved 
in the pharmacological action of [Ag(EIA)2]Cl, we reacted the silver complex with three 
model proteins: cytochrome C, ribonuclease A, and lysozyme. We analyzed the 
incubated solutions through a well-established protocol relying on high-resolution 
mass spectrometry (HRMS) [11]. Indeed, binding and interaction with non-genomic 
targets such as proteins is recognized to play a key role for the activity of silver and gold 
carbene complexes [7, 10]. In contrast to expectations, no evidence of adduct 
formation was detected, even for incubation times up to 72 h.  
Fluorescence microscopy 
Finally, to evaluate the intracellular distribution of [Ag(EIA)2]Cl, SH-SY5Y cells were 
treated with this silver complex for various time periods and then observed by 
fluorescence microscopy. No fluorescence signal was detectable in the control cells 
(Figure 7 A). Conversely, a weak blue fluorescence signal appears in the peripheral 
cytoplasm after about 30 min treatment with [Ag(EIA)2]Cl, reaching its maximum 
intensity at 60 min. By observation of the fluorescence pattern, the fluorescent 
complex seems to accumulate within rounded bodies compatible with endocytic 
vesicles, as suggested by their distribution in the sub-plasmalemmal cytoplasm (Figure 
7B).  
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Fig.7: Representative image of SH-SY5Y cells: A) controls, and B) cells treated with 10 
M [Ag(EIA)2]Cl for 1 h. 
Conclusions 
There is currently broad interest in the development of metal carbene complexes 
combining cytotoxic and fluorescence properties. Herein we have reported on the 
synthesis and chemical characterization of a novel monocationic silver(I) NHC complex, 
namely bis(1-(anthracen-9-ylmethyl)-3-ethylimidazol-2-ylidene) silver chloride, bearing 
an anthracenyl fluorescent probe. The complex was fully characterized by NMR, ESI-
MS, elemental analysis, and X-ray crystallography. The chemical and biological 
characterization of this compound has revealed a few peculiar and interesting features. 
Quite surprisingly, replacement of the methyl group of Ag(MIA)Cl with an ethyl 
substituent at position 3 of the imidazole ring leads to the formation of a cationic silver 
complex bearing two carbene ligands. The selective obtainment of the bis-carbene 
complex is attributable to a number of factors including steric hindrance of the 
imidazole substituent, already reported by Garrison and Youngs [12]. [Ag(EIA)2]Cl is 
highly stable in common organic solvents or in buffered physiological solutions and is 
unreactive toward small model proteins. These properties make it highly suitable for 
biological and cellular studies. Remarkably, [Ag(EIA)2]Cl manifested cytotoxic potency 
10-fold higher than cisplatin and 2-fold higher than Ag(MIA)Cl when assayed in a 
reference neuroblastoma cell line (the respective IC50 values are 1.059, 9.987, and 
2.093 M). The in vitro pharmacological activity of [Ag(EIA)2]Cl correlates well with its 
capacity to enter cancer cells; this, in turn, probably depends on its greater lipophilicity 
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than that of Ag(MIA)Cl or cisplatin. [Ag(EIA)2]Cl potently inhibits TrxR with an IC50 value 
of 0.493 M; interestingly, this value is in good agreement with the determined 
cytotoxicity value, supporting the view of TrxR as one of the likely cellular targets. The 
reaction of [Ag(EIA)2]Cl toward the C-terminal dodecapeptide of thioredoxin reductase 
hTrxR (488–499) was investigated by HRMS experiments. Notably, [Ag(EIA)2]Cl is able 
to bind tightly the C-terminal fragment, most probably at the level of the S-Se redox 
motif, through an unconventional mechanism, involving a sort of transmetalation, with 
concomitant loss of the silver center. This finding is particularly important, and, to the 
best of our knowledge, such a mode of binding is reported here for the first time. 
Finally, it is notable that the presence of the anthracene fluorophore allows facile 
tracking of the complex by fluorescence microscopy analysis; we found that [Ag(EIA)2]Cl 
accumulates within rounded-shaped bodies that are compatible with endocytic 
vesicles. 
Experimental Section 
Chemistry  
Synthesis were carried out through modifications of those reported in the literature [7, 
12]. The overall synthetic route is displayed in Scheme 1.  
 
Scheme 1: Synthetic route for bis(1-(anthracen-9-ylmethyl)-3-ethylimidazol-2- ylidene) 
silver chloride. 
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Fig.8: System numeration. 
Synthesis of 3-(anthracen-9-ylmethyl)-1-ethyl-1H-imidazol-3-ium chloride (5): To 
compound (4) (210 mg, 0.9 mmol) was added ethylimidazole(2 ml, 25 mmol). The 
obtained mixture was stirred for 24 h at room temperature. Next, acetonitrile was 
added to the mixture to induce precipitation of compound as chloride salt. The 
resulting solid was filtrated and washed with ether. Yield: 75%. 
1HNMR (400.13 MHz, DMSO-d6) δ: 9.04 (s, 1H, Im H2’), 8.83 (s, 1H, Ant H10), 8.46 (d, 
2H, Ant H1, J = 8.8 Hz), 8.21 (d, 2H, Ant H4, J = 8.3 Hz), 7.77 (s, 1H, Im, H4’) 7.67 (pseudo 
t, 2H, Ant H2), 7.65 (s, 1H, Im, H5’), 7.60 (pseudo t, 2H, Ant H3), 6.47 (s, 2H, AntCH2Im), 
4.09 (q, 2H, ImCH2CH3, J = 7.2 Hz), 1.30 (t, 3H, ImCH2CH3, J = 7.2 Hz);  
13CNMR (100.61 MHz, DMSO-d6) δ: 135.46 (Im C2’), 131.02 (Ant C4a), 130.58 (Ant C8a), 
130.01 (Ant C10), 129.30 (Ant C4), 127.69 (Ant C2), 125.50 (Ant C3), 123.56 (Ant C9), 
123.44 (Ant C1), 122.40 (Im C5’), 122,10 (Im C4’), 44.78 (AntCH2Im), 44.14 (ImCH2CH3), 
15.11 (ImCH2CH3). 
Synthesis of bis(1-(anthracen-9-ylmethyl)-3-ethylimidazol-2-ylidene) silver chloride 
([Ag(EIA)2]Cl): Compound 5 (101 mg, 0.31 mmol) was stirred with silver(I) oxide (40 mg, 
0.17 mmol) in methanol (7 mL) for 24 h. Then, dichloromethane (20 mL) was added to 
the mixture and the suspension was filtered over Celite to remove both unreacted Ag2O 
and AgCl formed during reaction. After concentration in vacuo, crystallization was 
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carried out at -20 °C by adding hexane. During the next four days the dark-grey 
precipitate that slowly appeared was filtered off daily. Finally, the plate-shaped crystals 
of complex were filtered and washed with hexane. Yield: 61%;  
1H NMR (400.13 MHz, MeOD): =8.59 (s, 2H, Ant H10), 8.18 (d, 4H, Ant H1, J=8.1 Hz), 
8.07 (d, 4H, Ant H4, J= 8.2 Hz), 7.53–7.45 (m, 8H, Ant H2,3), 7.31 (s, 2H, Im H4’), 7.23 (s, 
2H, Im H5’), 5.91 (s, 4H, AntCH2Im), 3.58 (b, 4H, ImCH2CH3), 1.13 ppm (b, 6H, ImCH2CH3);  
13C NMR (100.61 MHz, MeOD): d= 183.57 (Im C2’), 133.05 (Ant C4a), 132.17 (Ant C8a), 
130.83 (Ant C10), 130.57 (Ant C4), 128.51 (Ant C2), 126.48 (Ant C3), 124.59 (Ant C9), 
123.67 (Ant C1), 123.22 (Im C5’), 121.53 (Im C4’), 48.25 (AntCH2Im), 47.82 (ImCH2CH3), 
17.07 ppm (ImCH2CH3);  
ESI-MS: m/z 681.20;  
Elemental analysis of C, N, and H for C40H36AgClN4·3(CH2Cl2) [calculated C: 53.20 %, H: 
4.36 %, N: 5.77 %, experimental: C: 53.22 %, H: 4.04 %, N: 5.02%]. 
Synthesis of 3-(anthracen-9-ylmethyl)-1H-imidazole (6): Imidazole (84.9 mg, 1.25 
mmol) was stirred overnight in 10 mL of DMF with 172.3 mg (1.25mmol) of K2CO3 and 
309.3 mg (1.36 mmol) of 4 at 60°C. Subsequently, 50 mL of water were added and the 
mixture was extracted with CH2Cl2, washed with water and dried with Na2SO4.Yield: 
43%.  
1HNMR (400.13 MHz, CDCl3) δ:8.57 (s, 1H, Ant), 8.20 (d, 2H, Ant, J = 8.57 Hz), 8.08 (d, 
2H, Ant, J = 7.83 Hz), 7.57(m, 2H, Ant), 7.51(m, 2H, Ant), 7.48 (s, 1H, Im), 6.99 (s, 1H, 
Im), 6.86 (s, 1H, Im), 6.09 (s, 2H, AntCH2Im) 
Synthesis of 3-(anthracen-9-ylmethyl)-1-propyl-1H-imidazol-3-ium bromide (7): 
Compound (6) (49.47 mg, 0.19 mmol) was dissolved in 2 mL of CH3Cl. Subsequently 5 
mL of 1-Bromopropane were added to the solution. The obtained mixture was stirred 
at 60°C. After 6h diethyl ether was added to the mixture to induce precipitation of 
compound as bromide salt. Yield: 86%.  
1HNMR (400.13 MHz, DMSO-d6) δ:8.95 (s, 1H, Im), 8.85 (s, 1H, Ant), 8.45 (d, 2H, Ant, J 
= 8.76 Hz), 8.23 (d, 2H, Ant , J = 8.32Hz), 7.75 (s, 1H, Im), 7.68 (m, 2H, Ant), 7.66 (s, 1H, 
Im), 7.62 (m, 2H, Ant), 6.48 (s, 2H, AntCH2Im), 4.03 (t, 2H, ImCH2CH2CH3, J = 7.07 Hz), 
1.69 (m, 2H, ImCH2CH2CH3), 0.73 (t, 3H, ImCH2CH2CH3, J = 7.37 Hz). 
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13CNMR (100.61 MHz, MeOD) δ: 137.51, 132.96, 132.50, 131.99, 131.28, 129.62, 
127.45, 125.33, 125.19, 124.49, 124.37, 52.14, 46.80, 24.71, 12.08. 
Synthesis of bis(1-(anthracen-9-ylmethyl)-3-propylimidazol-2-ylidene) silver bromide 
([Ag(PIA)2]Br): 51.7 mg of (7) (0.13 mmol) were stirred with silver(I) oxide (17.9 mg, 
0.075 mmol) in methanol (2.5 mL) for 24 h. Then, 10 mL of dichloromethane were 
added to the mixture and the suspension was filtered for removing the solid phase. 
After concentration in vacuum, crystallization was allowed at -20° C by adding hexane. 
During the next four days the dark-grey precipitate that slowly appeared was daily 
filter-off.  Finally, the crystals of complex were filtered and washed with hexane. Yield: 
61%.  
1HNMR (400.13 MHz, MeOD) δ: 8.61(s, 1H, Ant), 8.19 (d, 2H, Ant, J = 8.41 Hz), 8.08 (d, 
2H, Ant, J = 7.45 Hz), 7.54 (m, 6H, An t+ Im overlapped), 5.92 (s, 2H, AntCH2Im), 3.43(b, 
2H, ImCH2CH2CH3), 1.46(b, 2H, ImCH2CH2CH3), 0.57(b, 3H, ImCH2CH2CH3) 
13CNMR (100.61 MHz, MeOD) δ: 190.51, 133.09, 132.21, 130.89, 130.67, 130.58, 
129.22, 128.50, 126.64, 126.50, 124.60, 123.84, 123.61, 123.23, 54.98, 47.88, 25.67, 
11.16 
Spectrophotometric analysis: Solution behavior of [Ag(EIA)2]Cl was assessed by 
spectrophotometric studies performed with a Varian Cary 50 Bio UV/Vis 
spectrophotometer. For absorption experiments solutions of complex (10-5M) were 
prepared in dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF) or 50 mm 
phosphate buffer (pH 7.4) in the presence of 1% of organic solvent. Emission spectra of 
complex (10-8M), in 50 mm phosphate buffer (pH 7.4) with the presence of 0.001% of 
DMF, were recorded with a PerkinElmer LS55 Luminescence Spectrometer. All the 
experiments were carried out at 25 °C. 
LogP determination: The octanol/water partition coefficient was assessed through a 
modified shake-flask method previously used in our laboratories [8]. 
NMR spectroscopy: NMR spectra were acquired on a Bruker Avance III 400 console 
equipped with a Bruker Ultrashield 400 Plus superconducting magnet (resonating 
frequencies: 400.13 and 100.61 MHz for 1H and 13C NMR, respectively) and a 5 mm 
PABBO BB-1H/D Z-GRD Z108618/0049 probe. All spectra were recorded at room 
temperature (25 +/- 2 °C) in solvents with a deuteration degree of 99.8% and calibrated 
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on solvent residual signals [13]. CDCl3 was purchased from Sigma–Aldrich, while DMSO-
d6 was purchased from Deutero.de (https://www.deutero.de/).  
ESI-MS: Interaction between the silver complex and the synthetic dodecapeptide Ac-
SGGDILQSGCUG-NH2, corresponding to the C terminal tryptic fragment of hTrxR, was 
assessed by high-resolution ESI-MS [6a, b]. The dodecapeptide was dissolved in LC–MS-
grade water (final concentration 10-4M solution), and dithiothreitol (DTT, 5.0 equiv) was 
added to reduce the S-Se bond. Then, the silver complexes (1.0 equiv) were also added 
at a 1:3 metal complex/peptide molar ratio, and the mixture was incubated for 2 h at 
37 °C. Interaction between [Ag(EIA)2]Cl and model proteins was carried out as 
described in our previous works [11]: solutions of cytochrome C, ribonuclease A, and 
lysozyme (10-4M) were incubated for 72 h at 37 °C with [Ag(EIA)2]Cl (3:1 complex to 
protein ratio) in 20 mM ammonium acetate buffer (pH 6.8) in the presence of 3% of 
organic solvent (DMSO or DMF). Aliquots were sampled after 24, 48, and 72 h. ESI-MS 
spectra were acquired through direct infusion at 10 mL/min flow rate in a TripleTOF-
5600+ mass spectrometer (Sciex, Framingham, MA, USA), equipped with a DuoSpray 
interface operating with an ESI probe. The ESI source parameters were optimized as 
follows: positive polarity, ionspray voltage floating 5500 V, temperature 400 °C, ion 
source gas 1 (GS1) 40, ion source gas 2 (GS2) 30, curtain gas (CUR) 25, declustering 
potential (DP) 100 V, collision energy (CE) 10 V. For acquisition, Analyst TF software 
1.7.1 (Sciex) was used, and deconvoluted masses were obtained by using the Bio Tool 
Kit micro-application v.2.2 embedded in PeakView_ software v.2.2 (Sciex).  
X-ray crystallography: Single crystals suitable for X-ray diffraction experiments for EIA 
were obtained by adding to the reaction mixture acetonitrile and diethyl ether. This 
solution was stored at -20 °C for four days. After this time, yellow needle-shaped 
crystals were obtained. For [Ag(EIA)2]Cl, colorless plate-shaped crystals were 
straightforwardly obtained as products of the synthesis as described above in the 
paragraph reporting synthesis of the compound. Similarly, for [(Ag(PIA)2]Br, suitable 
crystals were obtained as product of the synthesis. Data collection was performed on 
an Oxford Diffraction Xcalibur3 diffractometer at 100 K and with MoK radiation ( = 
0.71073 Å). Data collection and reduction were performed through the suite CrysAlis 
[14]. The absorption correction was applied with the program SCALE3 ABSPACK, also 
integrated in the CrysAlis suite. The structures were solved by direct methods 
implemented in SIR97 [15] and refined by full-matrix least-squares on F2 using the 
SHELXL software package [16]. All non-hydrogen atoms were refined anisotropically by 
full-matrix least-squares methods on F2. All H atoms (except those of H2O in 5) were 
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placed in calculated positions with isotropic thermal parameters depending on that of 
the atom to which they are bound and included in structure factor calculations in the 
final stage of full-matrix least-squares refinement. In the crystal structure of compound 
[Ag(EIA)2]Cl, the silver and chlorine atom lie in special position and the occupancy factor 
is 0.5 for both atoms. Supplementary crystallographic are reported in Table 4. These 
data can be obtained free of charge from The Cambridge Crystallographic Data Centre.  
 
Table.4: Crystallographic Data of compounds 5, [Ag(EIA)2]Cl and [Ag(PIA)2]Br. 
Cell culture: Human SH-SY5Y neuroblastoma cells were cultured in Dulbecco’s modified 
Eagle’s medium/Ham’s Nutrient Mixture F12 (1:1) (Sigma–Aldrich), supplemented with 
10% heat-inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), 2 mm 
glutamine, 250 U/mL penicillin G and 250 mg/mL streptomycin (Sigma–Aldrich), in a 
humidified atmosphere with 5% CO2 at 37 °C.  
Cytotoxicity assay: Cell viability was measured using the CellTiter-Blue Reagent 
(Promega, Milan, Italy). SH-SY5Y cells (1x104 per well) were seeded in 96-well plates 
and treated with [Ag(EIA)2]Cl (0.5–2.5 M), cisplatin (10–50 M), and [Ag(MIA)]Cl (2–
10 M) for 24 h. At end treatments, CellTiter-Blue Reagent was added to each well and 
5 [Ag(EIA)2]Cl [Ag(PIA)2]Br 
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incubated for 2 h at 37 °C. Fluorescence was measured in a multiplate reader (Infinite 
M200PRO, Tecan, Switzerland) at 560/590 nm. The IC50 values for each compound 
were determined from the specific dose–response curves by nonlinear analysis, using 
GraphPad Prism 2.0 statistical software (GraphPad Software, San Diego, CA, USA) and 
expressed as means +/- standard deviation of at least four independent experiments. 
Drug uptake: SH-SY5Y cells were seeded in six-well plates (5x105 cells per well) and 
allowed to adhere. The culture medium was replaced with medium without phenol red 
and FBS, and the cells were incubated with [Ag(EIA)2]Cl, cisplatin, or [Ag(MIA)]Cl (10 
M) for 30 min. At end of treatments, the cells were harvested in distilled H2O to induce 
osmotic shock. The determination of metals concentration in the cell lysates was 
performed as previously reported [8] in triplicate by a Varian 720-ES inductively 
coupled plasma atomic emission spectrometer (ICP-AES) equipped with a CETAC U5000 
AT+ ultrasonic nebulizer, in order to increase the method sensitivity. Before analysis, 
fixed volumes of samples were moved in vials and digested in a thermo-reactor at 80 
°C for 3 h with 1 mL of aqua regia (HCl supra-pure grade and HNO3 supra-pure grade in 
3:1 ratio) and 5 mL of ultrapure water (R > 18 M). Next, samples were spiked with 1 
ppm of Ge used as an internal standard and analyzed. Calibration standards were 
prepared by gravimetric serial dilution from a commercial standard solution of Pt at 
1000 mg/L. The wavelength used for Pt and Ag determination were 214.424 and 
338.289 nm, respectively, whereas for Ge the line at 209.426 nm was used. The 
operating conditions were optimized to obtain maximum signal intensity, and between 
each sample, a rinse solution of HCl supra-pure grade and HNO3 supra-pure grade at a 
3:1 ratio was used to avoid any “memory effect”. The values of Ag or Pt were 
normalized to cellular proteins, determined by the micro-bicinchoninic acid (BCA) 
method, and expressed as mg metal per mg protein. Intracellular localization of 
[Ag(EIA)2]Cl monitored by fluorescence microscopy: SH-SY5Y cells (5x105) were seeded 
on a glass coverslip and treated with 10 mm [Ag(EIA)2]Cl for 20, 30, 60, and 90 min. 
Control cells, not treated with this silver complex, were used. At end of treatment, the 
cells were fixed with 2% paraformaldehyde for 10 min at room temperature and then 
observed under an epifluorescence Zeiss Axioskop microscope (Mannheim, Germany) 
using 358 nm excitation wavelength, with a 100X objective. The fluorescence images 
were captured using a Leica DFC310 FX 1.4-megapixel digital camera, equipped with 
the Leica software application suite LAS V3.8 (Leica Microsystems, Mannheim, 
Germany). 
TrxR activity assay: The inhibitory effects of complex toward TrxR activity (from rat 
liver) were determined by quantification of the ability of compound to directly reduce 
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5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) in the presence of NADPH as reported 
previously [10]. 
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8. Final considerations 
As Barnett Rosenberg stated in last years of his life, the results obtained by chemists in 
developing new anticancer compounds have been substantially inadequate (Fig.1). For 
this reason, all the scientists involved in the field of medicinal bioinorganic research 
should address their efforts in finding safer and more effective metal-based drugs, to 
be used as anticancer or antimicrobial agents, being the cancer and bacterial infections 
two between the most lethal global health problems. As I showed in previous chapters, 
this family of molecules still has a lot to offer in the field of clinical applications. The 
wide literature concerning their structural modifications teaches us that the family of 
transition metal complexes could be an almost limitless repository of valuable drug 
candidates. We only need of enough hands and motivation for not stopping our 
research work. Anyway, it is also a moral duty. 
 
Fig.1: “For years I've been saying this is the first platinum-based drug we discovered 
(Cisplatin). It can't possibly be the best one. It's disappointing that the scientific 
community has not been able to find better ones” [1]. Barnett Rosenberg (1926-2009), 
the discoverer of anticancer activity of Cisplatin. 
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